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Abstract 
Despite decades worth of research, glioblastoma remains one of the most lethal 
cancers.  The identification of IDH1 as a major cancer gene in glioblastoma provides an 
exceptional opportunity for improving our understanding, diagnostics, and treatment of 
this disease.  In addition to mutations in IDH1, recent studies from our laboratory have 
characterized the genetic landscape of gliomas and have shown the cooperation between 
IDH1 mutations and other oncogenic alterations such at TP53 mutations.  Normally, 
IDH1 functions in the oxidative decarboxylation of isocitrate to α-ketoglutarate, 
however the mutant form confers neomorphic enzymatic activity by producing D-2-
hydroxyglutarate, an oncometabolite responsible for aberrant methylation in IDH1-
mutated tumors, among other mutant IDH1-mediated phenotypes.  To determine the 
role of mutant IDH1 in vivo, we generated a conditional knock-in mouse model.  This 
genetically faithful system is both biologically and clinically relevant and will promote 
the understanding of mutant IDH1-mediated tumorigenesis while offering a route for 
therapeutic targeting. 
We observed that broad expression of mutant IDH1 throughout the brain leads 
to hydrocephalus in 80% of animals.  In assessing the earliest effects of mutant IDH1 on 
the brain, we determined mutant IDH1 confers a decrease in the proliferative cells of the 
subventricular zone of the lateral ventricle, the area which houses the neural stem cells 
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in embryonic and adult animals.  Additionally, a perturbation to the normal neural stem 
cell niche was observed in these animals.  Combined, this data suggests that mutant 
IDH1 may be affecting the signaling pathways involved in differentiation in this 
population of cells.  In vivo and in vitro studies will further elucidate mutant IDH1’s 
effects on the differentiation patterns of neural stem cells expressing mutant IDH1. 
To express mutant IDH1 in a more restricted manner and harness spatio-
temporal control, we crossed mutant animals to a Nestin-CreERT2 strain of mouse that 
permits expression of floxed alleles upon treatment with tamoxifen.  Animals were 
sacrificed at the onset of symptoms or at 1-year of age.  We observed the development of 
both low- and high-grade gliomas in approximately 15-percent of E18.5 tamoxifen-
treated animals.  All tumors were found in a TP53-deleted background with mutant 
IDH1 being detected in only those tumors with the mutant allele.  Lastly, to decrease the 
latency and increase the penetrance of tumor formation, an orthotopic intracranial 
injection model was generated to allow for visualization of tumor formation and 
development, as well as investigation of therapeutic modalities.  The models generated 
and the knowledge gained from these studies will offer an understanding of the 
biological effects of the most common mutations found in the astrocytic subset of 
gliomas, bringing us strides closer to determining mechanisms and therapeutic targets 
for IDH1-mutated cancers.
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1.1  Introduction:  Gliomas 
Gliomas are the most common primary tumor of the central nervous system 
accounting for approximately 30 percent of all brain tumors and 80 percent of all 
malignant brain tumors.  It is estimated that in 2014 alone, 66,240 patients will be newly 
diagnosed with about 14,320 patients succumbing to the disease, making brain tumors 
the second leading cause of cancer-related deaths among children and males, and the 
fifth leading cause of cancer-related deaths among females(1,2).   
Despite decades worth of research, the overall survival for patients with high-
grade glioma remains dismal with a median survival of only 15 months(3).  In fact, over 
the past four decades, the survival for this disease has remained mostly unchanged 
(Figure 1).  This stagnant improvement in survival is made even more apparent when 
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compared to other cancers that have exhibited significant increases in survival over the 
past several years, including colon cancer, esophageal cancer, breast cancer, prostate 
cancer, and several hematopoietic cancers, among others(1,4).   
 
 
Figure 1:  New cases, deaths and 5-year relative survival for brain and other 
nervous system cancer.   
Brain and other nervous system cancers account for about 1.4% of newly 
diagnosed cancers in 2014.  Though there has been a slight increase in the number of 
new cases in the past few decades, there has been only minimal improvement in 5-
year survival.  This data, adapted from the SEER Cancer Statistics Review shows all 
brain and nervous system cancers.  The lack of improvement is even more apparent 
when looking at glioblastoma specifically(1). 
 
The difficulties in treating and curing gliomas lie in several features.  First, the 
brain is encased in a non-compromising skull; any aberrant growth within this confined 
area inevitably leads to compression, increased pressure, and ultimately neurological 
symptoms and dysfunction.  Second, tumor growth in this area of confined space is 
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likely to interfere with the vital structures present within it.  For similar reasons, 
resection is usually incredibly difficult and often times, incomplete.  Third, gliomas tend  
to be highly infiltrative with microscopic spread of tumor.  Even when resection appears 
complete, these microscopic foci promote regrowth.  Lastly, due to the blood-brain-
barrier as well as cell-intrinsic factors, glioma cells are largely resistant to many current 
therapeutics(5).   
Understanding the molecular underpinnings of this most fatal disease is of the 
utmost importance.  To this end, we sought to determine the genetic aberrations most 
commonly found in gliomas, recapitulate the human disease through generation of 
genetically faithful mouse models and to utilize these models for both understanding 
the development and progression of these tumors, as well as investigation of therapeutic 
modalities.  
This chapter will present background to gliomas as a disease and encompasses 
their classification, etiology through looking at normal developmental programs of cells 
of the central nervous system (CNS), as well as a discussion of the suspected cell of 
origin for gliomas.  Subsequent chapters will discuss our work in determining the 
genetic signatures of gliomas, generation of our genetically faithful mouse models that 
harbor those mutations we identified in our signatures, followed by a mechanistic look 
at how these mutations in our genetic signatures function to promote tumorigenesis. 
 4 
1.1.1  World Health Organization Classification of Tumors 
The World Health Organization (WHO) categorizes the over 120 different types 
of brain tumors based on the cells that the tumor is composed of as well as the behavior 
of the tumors themselves.  Histologic features, genetic aberrations, and malignant 
behavior are all taken into account when grading these tumors on a scale of I through 
IV.  Grade I tumors exhibit low proliferative activity and the great potential for cure 
following surgical resection(6).  Grade II tumors are low-grade malignancies with low 
levels of mitotic activity.  Their tendency to be diffusely infiltrative makes complete 
resection difficult and thus recurrence and progression to higher-grade lesions 
prevalent(7,8).  Median survival among patients diagnosed with Grade II tumors is 5 to 
7 years.  Grade III tumors display histological evidence of malignancy, including nuclear 
atypia and mitotic activity.  Patients with Grade III tumors display a median survival of 
2 to 5 years(3).  Similar to Grade II tumors, Grade III tumors can progress to the 
secondary Grade IV tumors which include the glioblastomas (GBMs).  These tumors are 
malignant, mitotically active, and display necrosis, increased cellularity, and 
microvascular proliferation(8).  The invasive nature, rapid proliferative capacity, and 
ability of recurrence gives patients diagnosed with GBM a dismal median survival of 
only 12 to 15 months(3).  Grade IV GBMs can be further subdivided into primary and 
secondary GBM, with primary GBM arising de novo and secondary GBM arising as a 
progression from lower grade lesions including Grade II and Grade III tumors.  Though 
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histologically very similar and often impossible to distinguish histologically, primary 
and secondary GBM are genetically distinct diseases. 
1.1.2  Neural Development and Cells of the CNS 
By the end of gastrulation, neural stem cells (NSCs) are poised to give rise to all 
cell types of the CNS of the developing organism, including but not limited to, neurons 
and glial cells which include the astrocytes and oligodendrocytes.  Following emergence 
of the neural plate, two folds will form and fuse, generating the neural tube.  The NSCs 
will form a single layer of cells lining the center of the neural tube, which will ultimately 
become the ventricles of the brain.  The neural progenitor cells in the most rostral region 
of the neural tube give rise to the brain.  Rapid growth ensues forming the primary brain 
vesicles including the prosencephalon, the mesencephalon, and the rhombencephalon, 
the primitive structures of the forebrain, midbrain, and hindbrain, respectively(9).  
Neuron production will occur through gestation, and once produced, they will migrate 
away from the proliferative regions of the ventricular zone to their proper location 
among the six-layered neocortex.  During this period, neural progenitor cells divide 
symmetrically in order to populate the many cells that are required for the functional 
brain.  As time progresses, asymmetric divisions commence with the progenitor cell 
remaining in the proliferative zone, and the differentiated cell migrating outwards to 
take its place in the cortex.  As the brain develops and expands, radial glial cells are 
enlisted to form tracks on which the migrating neurons can follow.  The radial glial cells 
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will extend basal processes that attach to the pial surface of the brain while their nucleus 
is anchored in the ventricular zone allowing for migrating neurons to populate their 
respective cortical layers in an “inside-out” fashion, with earlier migrating neurons 
forming the deepest layers of the brain (layer VI), and later migrating neurons forming 
the more superficial layers (layer I)(9).   
Though neurogenesis peaks during gestation, it does occur in the adult brain, 
specifically in the subventricular zone (SVZ), an epithelium that lines the walls of the 
lateral ventricle, as well as in the subgranular layer of the dentate gyrus of the 
hippocampus, though not nearly as robust as during fetal development(10).  The glial 
progenitors give rise to the major support cells of the CNS, the glial cells, which generate 
more than 50% of the cells in the human brain and are suspected of dividing and 
differentiating for an extended period after birth, and even through adult life(11).  The 
glial cells include the astrocytes and oligodendrocytes.  Astrocytes function in providing 
structural support, regulating water balance and ion distribution, and maintaining the 
blood-brain barrier.  Additionally, astrocytes have roles in neuropeptide production and 
synaptic transmission, as well as implications in response to injury.  On the other hand, 
oligodendrocytes ensheathe neuronal axons with myelin to provide insulation and 
facilitate signal conduction. 
As mentioned, neurogenesis precedes gliogenesis and the transition is referred to 
as the gliogenic switch.  This switch is believed to be induced through a variety of 
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factors that are usually location dependent, however recent studies have shown signals 
from differentiated neurons may induce astrocytic differentiation(12-14).  Astrocyte 
precursors have the ability to undergo robust proliferation outside of the typical 
germinal centers of adult animals and in doing so, are able to generate both transit 
amplifying astrocytes as well as multipotent NSCs(15).  This suggests that under certain 
conditions, normal astrocytes have inherent properties similar to those of NSCs. 
Oligodendrocytes, another type of glial cell that arises from the expansion and 
differentiation of NSCs, are formed from multiple progenitor pools throughout the 
developing embryo.  In the postnatal brain however, the major source of 
oligodendroglial progenitor cells (OPCs) is in the SVZ at the tips of the lateral ventricles.  
From here, the OPCs will migrate into the white matter where they will stop dividing 
and differentiate to form mature myelinating oligodendrocytes(14).  Additionally, a 
population of OPCs can be found in the white matter itself. 
Humans undergo prolonged neural development, with the prefrontal cortex 
being one of the last components to mature.  It is not until 10 years of age that the brain 
reaches its adult volume.  Myelination continues well into adolescence and into early 
adulthood.  At this time, synaptic pruning correlates with a loss of prefrontal grey 
matter and this reorganization of the prefrontal cortex is what is believed to impart 
higher cognitive processes including executive function, social cognition and 
judgment(16).  It is possible that this structural reorganization of the prefrontal cortex 
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and subsequent change in gene expression, migration, and metabolic utilization during 
adolescence may impart a susceptibility to these cells making them more prone to 
mutagenic hits, and thus tumorigenesis. 
1.1.3  Cell of Origin for Gliomas 
The identification of the cell of origin for a cancer opens up several avenues of 
pursuit that ultimately leads to great potential in understanding the biology behind 
tumor development as well as offering a more concise means of therapeutic 
investigation.  Unfortunately, such a pursuit for gliomas has been hindered by 
difficulties in ascertaining the specific cell of origin for this devastating disease.  Though 
a precise cell of origin is unknown, there are several suitable candidates including NSCs, 
OPCs, transit amplifying cells, or differentiated glial cells that either undergo a process 
of dedifferentiation or become fully transformed(17).  The fact that gliomas can be 
composed largely of astrocytes (astrocytomas), oligodendrocytes (oligodendrogliomas), 
or a mixture of the two (oligoastrocytomas), contributes to the difficulties of resolving a 
specific cell type as a cell of origin. 
NSCs are one of the leading candidates as the cell of origin for gliomas.  There 
are many shared features between NSCs and cancer cells of the CNS; they both exhibit 
robust proliferation that is coupled with the potential to generate a diversity of progeny.   
Additionally, the behavior among NSCs and cancer cells of the CNS are similar.  For 
example, both display high motility, an affinity for blood vessels and white matter 
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tracts, and perhaps most interesting, both have activation of similar developmental 
signaling pathways(18).  Experimental data implicating NSCs as the cell of origin for 
gliomas is on the rise.  In animal models, when areas which housed the NSCs were 
infected with virus for oncogene delivery, these cells underwent transformation and 
induced formation of GBM(19).  This was not observed when the oncogenes were 
delivered to differentiated astrocytes, suggesting that the NSC population is more 
susceptible to transformation.  NSCs inherently have certain expression patterns 
activated, including pro-mitotic genes, telomerase activity, and anti-apoptotic genes.  By 
comparing this pattern of expression to those of other, more differentiated cell types, it 
becomes plausible to figure these cells are already en route to being fully transformed.  
Lastly, if NSCs are the cell of origin for gliomas, it would explain the observed 
heterogeneity.  As NSCs or progenitor cells are capable of differentiating into astrocytes 
or oligodendrocytes, the stage at which a NSC becomes transformed could theoretically 
dictate whether a tumor is predominately astrocytic, oligodendrocytic, or a mixture of 
the two. 
In an extension of the first endogenous genetic tumor suppressor mouse model, 
it was found that embryonic, early postnatal, and adult NSCs can give rise to malignant 
astrocytomas in vivo(20).  The same was not observed when these same mutations were 
incorporated into mature cell types.  This lends credence to the hypothesis that NSCs are 
the cell of origin for gliomas. 
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Alternatively, another candidate for the cell of origin for gliomas are the OPCs.  
In an elegant study utilizing mosaic analysis with double markers (MADM), a system 
permitting lineage tracing and subsequent analysis of individual cell lineages and their 
implication as cells of origin, Liu et al., show that gliomagenesis only occurred when 
mutations were incorporated in NSCs that gave rise to mutant OPCs(21).  Cells that 
were derived from NSCs, but were not OPCs failed to generate tumors.  This suggests 
that even if a mutation occurs in the NSC, only if they are able to generate OPCs with 
the mutation, will tumors develop; thus stressing the importance of a mutations cellular 
dependency.   
The precise cell of origin for gliomas is unknown.  Though there are candidates 
available: either NSCs, OPCs, or differentiated glial cells, the heterogeneity of the 
tumors themselves may suggest that these are distinct diseases each with their own 
respective cell of origin(17,22).  It may be possible that the different subtypes of gliomas 
originate from different cell of origins, or it may be that they originate from the same cell 
of origin, but as the tumor develops, gives rise to different cell types via differentiation, 
mutation acquisition, or cues from the microenvironment.   
Due to the convincing body of literature implicating NSCs as the cell of origin, 
we have centered our studies on generating genetically faithful mouse models with the 
cell of origin for gliomas being the NSC.  These will be discussed further in subsequent 
chapters. 
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2.  Introduction:  Mutations in Isocitrate Dehydrogenase 
1 (IDH1) in Gliomas 
With the culmination of the Human Genome Project on April 14th, 2003, we have 
thus embarked on the Post-Genome era.  Having taken 13 years and approximately $2.7 
billion to complete, this endeavor has set the stage for tremendous advancements in 
understanding the molecular underpinnings of variation within humans as well as the 
genetic basis for disease.  With goals within reach of sequencing a genome at a cost of 
$1000 and the time to do so taking only a few days, efforts have been put forth to 
sequence and characterize the genomic aberrations present in human tumors.  Initiatives 
including The Cancer Genome Atlas (TCGA) have begun to sequence cancers with 
priority going towards those cancers exhibiting poor prognosis and an overall public 
health impact.  To date, TCGA has successfully and completely sequenced 31 cancers, 
with data for all but 4 ready for public availability. 
Due to the dismal prognosis and the inability to improve survivability, GBM was 
one of the first cancers to be sequenced by the TCGA in an effort to acquire a baseline 
knowledge of GBM genetics(23).  Similar efforts from our group in collaboration with 
others, focused on a brute-force genome-wide mutational analysis of GBM where 20,661 
protein coding genes were sequenced in 22 GBMs(24).  In addition to sequencing, focal 
copy number alterations including amplifications and deletions, as well as gene 
expression studies were performed.  The ultimate goal was to determine the genetic 
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alterations in GBM for application towards diagnostics, prognostics, and therapeutic 
targeting.  Several findings resulted from these studies.  For one, many of the molecular 
features already identified to have a pathogenic role in GBM were validated.  These 
included mutations in core components of the retinoblastoma tumor suppressor (RB), 
TP53 tumor suppressor, and receptor tyrosine kinase (RTK) pathways(23,24).  
Identification of disrupted pathways in GBM has provided guidance in determining 
treatment for patients, in among the first validations of personalized medicine for GBM.  
For example, patients with inactivating mutations in CDKN2A or CDKN2C or 
amplifications in CDK4 or CDK6 would be candidates for treatment with CDK 
inhibitors, however this treatment would likely be ineffective for patients with RB1 
mutations(23).  By elucidating those specific alterations in a patient-specific manner, 
therapeutics targeting those pathways directly can be investigated as opposed to a one-
size-fits-all therapeutic approach where those therapeutics could likely be instigating 
pathway activation, leading to ineffective treatment, or even more aggressive cancer 
growth. 
These genetic studies have additionally identified several pathways and genes 
previously unknown to be altered in GBM.  The most frequently mutated of these 
candidate genes is that of isocitrate dehydrogenase 1 (IDH1) found on chromosome 
2q33(24).  Subsequent larger and more comprehensive studies from our own lab has 
sequenced 445 CNS and 494 non-CNS tumors and found that not only was IDH1 
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mutated in GBM, but it was mutated in as high as 80 percent of a particular subset of 
gliomas.  The mutations were observed in the progressive gliomas, those tumors that 
arise as a progression from the Grade II, Grade III, and secondary Grade IVs(25).  IDH1 
was not mutated in any Grade I tumors and only 6 out of 123 primary GBMs; suggesting 
IDH1 is a relatively early hit in tumorigenesis and may be a driver for malignancy as the 
tumors progress from low-grade (Grade II) tumors to higher-grade tumors (Grade III 
and secondary Grade IV).  In fact, in comparing the genetics of gliomas as they progress, 
it was observed that mutations in IDH1 often precede other aberrations that were once 
thought to be very early hits including mutation of TP53 or chromosomal loss of 
1p/19q(26). 
Additionally, it was found that in those progressive gliomas that were not 
mutated in IDH1, the homologous gene, IDH2, was mutated.  Every mutation found in 
IDH1 was located at the 132nd residue, and it was most commonly mutated from 
arginine to histidine, however a series of missense mutations were observed at this 
residue(25).  In those tumors mutated in IDH2, it was the analogous residue that was 
affected, arginine-172, and it was most commonly mutated to a lysine.  Determining the 
functional effects of this mutation required inspection of the protein’s crystal structure 
where it was observed that Arg-132 in IDH1 (and similarly, Arg-172 in IDH2) lied in the 
active site of the enzyme, thereby suggesting that these mutations may have an effect on 
the normal enzymatic activity of IDH1(25).  In fact, in structural comparisons, it was 
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noted that when the substrate, isocitrate, is present and complexes with the wildtype 
form of the protein, it forms hydrogen bonds with Arg-132 of IDH1 (and similarly, Arg-
172 in IDH2).  However, the lack of appropriate side chains when arginine is replaced 
with histidine prevents isocitrate from making those hydrogen bonds within the active 
site of the enzyme.  The implication is that the enzyme-substrate affinity may be 
compromised when the mutant form is present(27).   
To assess the effects mutant IDH1 is having requires knowledge of its normal 
activity.  Normally, IDH1 acts in the tricarboxylic acid (TCA) cycle where it functions in 
the oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG) in a NADP+-
dependent manner(28).  This is one of the irreversible steps of the TCA cycle that is 
essential for cellular respiration.  To elucidate the effects mutant IDH1 has on 
metabolism, metabolite profiling was performed via liquid chromatography-
electrospray ionization-mass spectrometry (LC-MS) on cells transfected with either 
wildtype or mutant IDH1(29).  It was observed that in mutant cells, there was a loss of 
the oxidative decarboxylation function of isocitrate to form α-KG.  However, subsequent 
analyses including targeted triple-quadrupole LC-MS-MS validated that in IDH1 mutant 
cells, there was a gain of enzymatic function in the NADPH-dependent reduction of α-
KG to a new metabolic product, 2-hydroxyglutarate (2-HG)(29) (Figure 2).  2-HG was 
further detected in tumors at levels 100-fold higher in IDH1 mutant tumors than in IDH1 
wildtype tumors (5μmol to 35μmol 2-HG per gram of tumor tissue. 
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Figure 2:  Function of wildtype and mutant IDH1. 
Wildtype IDH1 normally functions in the oxidative decarboxylation of 
isocitrate to α-KG in an NADP+ dependent reaction.  This is an active component of 
the TCA cycle.  Mutant IDH1 confers neomorphic enzymatic activity in its production 
of 2-HG.  
 
The finding that the metabolic product of mutant IDH1 is production of 2-HG is 
interesting on several levels.  For one thing, there are patients with a disorder called D-2-
hydroxyglutaric aciduria usually caused by germline mutations in the gene D-2-
hydroxyglutarate dehydrogenase(30).  These patients generate elevated levels of 2-HG and 
present with many neurological phenotypes including developmental delay, epilepsy, 
and varying degrees of encephalopathy, as well as hypotonia, dysmorphic features, and 
cardiomyopathy(31).  Additionally, mild ventriculomegaly was observed as an 
enlargement of the frontal subarachnoid spaces and subdural effusions.  Several other 
patients also presented with delayed cerebral maturation and subependymal cysts(32).  
 16 
In patients that have L-2-hydroxyglutaric aciduria, there appears to be an increased risk 
for developing brain tumors as well.  One paper, a case series of four patients with this 
disease, describes the development of brain tumors ranging in diagnosis from primitive 
neuroectodermal tumor, oligodendroglioma, and low-grade astrocytoma(33).  The broad 
effects of 2-HG on the brain in these 2-hydroxyglutaric aciduria patients suggests that 2-
HG does in fact perturb cells of the CNS and offers good rationale for suspecting mutant 
IDH1’s ability to produce elevated levels of 2-HG as a major component for brain tumor 
induction. 
2.1  The genetic landscape of gliomas 
Rarely are tumors formed as a result of a single hit.  On the contrary, cancer is a 
disease of genomic alterations, requiring multiple hits to fully transform a cell and 
promote tumorigenesis.  The average number of mutations in common solid tumors 
(colon, breast, brain, or pancreas) is about 33 to 66 mutations(34).  Of course, depending 
on the tumor type, the suspected induction of the mutation, as well as the pathways that 
are involved, the number of mutations will vary.  For example, melanoma will harbor 
approximately 200 mutations per tumor likely due to ultraviolet light inducing 
mutations, whereas pediatric tumors harbor far fewer mutations, approximately 9.6 
mutations per tumor.  It is thus the purpose and consequence of these large sequencing 
projects to identify the mutations present in these tumors, screen for those mutations 
that have the most effect on tumorigenesis and are likely drivers, and subsequently 
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elucidate the biological ramifications of them.   Additionally, it will be imperative to 
determine how these mutations are cooperating to promote tumorigenesis. 
We have recently completed several studies determining the genetic landscape of 
progressive glioma(35-37).  Our initial study was in determining the genetic signature 
for the progressive astrocytomas, specifically the diffuse astrocytomas (Grade II), 
anaplastic astrocytomas (Grade III), and the secondary GBMs (Grade IV).  This involved 
the exome sequencing of a large cohort of tumors.  Subsequently, we sought to use the 
markers identified in our exomic sequencing studies, together with previously reported 
genetic markers to assess whether we can identify the various subtypes of gliomas via a 
DNA-based sequencing method that could complement the traditional histopathological 
means of diagnosis. 
2.1.1  The genetic landscape of progressive astrocytomas 
In an effort to establish the genetic landscape of progressive astrocytomas, we 
sequenced the exomes of a total of 57 gliomas.  Included in our cohort were 7 diffuse 
astrocytomas (Grade II), 16 anaplastic astrocytomas (Grade III), 2 oligoastrocytomas 
(grade II), 4 oligoastrocytomas (Grade III), 1 secondary GBM (Grade IV), and 27 primary 
GBM (Grade IV).   
2.1.1.1  Genetic alterations of diffuse astrocytomas (Grade II) 
Exome sequencing of 7 diffuse astrocytomas (Grade II) revealed 93 somatic 
mutations.  On average, Grade II astrocytomas contained 13 somatic mutations, with 
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92% of targeted regions covered by 10x high quality reads or more.  Copy number gains 
or deletions were not observed in these samples, however mutations in IDH1, ATRX, 
and TP53 were found to be co-mutated in 43% of the Grade II astrocytoma cohort. 
2.1.1.2  Genetic alterations of anaplastic astrocytomas (Grade III) 
Exome sequencing of 16 anaplastic astrocytomas (Grade III) revealed 576 
mutations.  On average, Grade III astrocytomas contained 36 somatic mutations with 
92% of targeted regions covered by 10x high quality reads or more.  In addition to co-
occurring mutations in IDH1, ATRX, and TP53, mutations in the Notch signaling 
pathway, including NOTCH1, NOTCH2, NOTCH4, and NOTCH2NL were observed in 
31% of the Grade III astrocytoma cohort.   
2.1.1.3  Genetic alterations of GBMs (Grade IV) 
Exome sequencing of 28 GBMs identified 1,177 somatic mutations.  Primary 
GBMs on average contained 42 somatic mutations with 93% of targeted regions covered 
by 10x high quality reads or more.  Copy number alterations were frequent in this cohort 
of tumors, averaging 32 events per tumor.  Confirming previous studies, the 
EGFR/PTEN/PI(3)K pathway was the most frequently affected pathway.  In our cohort, 
EGFR was altered in 46%, PTEN in 14%, PIK3CA in 10%, and PIK3R1 in 13% of 
GBMs(23,24,38,39).  Several of these above mutations were also identified in the lower 
grade gliomas.  Interestingly, PIK3CA mutations were found exclusively in IDH1 
wildtype tumors, those tumors displaying the worst survival.   
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2.1.1.4  Summation of the genetic landscape of astrocytomas  
In determining the genetic landscape of the progressive astrocytomas, we 
determined that there are not an overwhelming number of genetic aberrations that are 
present.  In the earliest of the progressive astrocytomas, there are on average 13 somatic 
mutations per tumor.  We corroborated previous data showing that there is a co-
occurrence of mutations in IDH1, ATRX, and TP53 in these tumors.  This signature 
persists throughout the astrocytic family of gliomas, suggesting their co-occurrence is 
imperative for the initiation, development and/or maintenance of the progressive 
gliomas.  Additionally, we identified that in the Grade III astrocytomas, several 
members in the Notch signaling pathway were mutated.  Lastly, we show that the 
mutation spectrum among primary and secondary GBMs is quite distinct, lending 
credence to the belief that though histologically similar, primary and secondary GBMs 
are genetically distinct diseases.  A thorough summation of the findings from this study 
can be found in Figure 3. 
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Figure 3:  The genetic landscape of progressive gliomas. 
Mutational analysis utilizing exome sequencing of matched tumor and normal 
pairs for 57 progressive astrocytomas, oligoastrocytomas, and GBMs.  (A) Distribution 
of mutation types (Nonsense, Missense, Frameshift/Indel, Other) are reported for each 
tumor.  (B) Depiction of mutation spectrum for each tumor is shown.  Represented are 
genes mutated in four or more gliomas.  The frequency (%) and number of gene 
alterations in the tumor cohort is represented on the right. 
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2.2  Refining the classification of malignant gliomas 
Based on previous publications, it appeared there were genetic markers that 
tended to associate more closely with certain subsets of gliomas over others.  These 
markers together with the mutation status of IDH1 and IDH2 had the potential to 
classify the various subtypes of gliomas.  This would offer a genetic-based strategy to 
diagnose tumors that would complement the current histopathology-based means of 
diagnosis, a process that often exhibits variability based on institution and misdiagnosis.  
To this end, we sought to assess whether we could utilize these markers to classify the 
various subtypes of gliomas.   
Prior exomic sequencing studies have shown the presence of mutations in 
homolog of Drosophila capicua (CIC) and far-upstream binding protein 1 (FUBP1) in CNS 
samples (40).  Separately, studies aimed at identifying genetic lesions of pancreatic 
tumors identified inactivating mutations in Alpha thalassemia/mental retardation syndrome 
X-linked (ATRX) in pancreatic neuroendocrine tumors(41).  An expansion of this study 
into tumors of other origin described that these tumors displayed the alternative 
lengthening of telomere (ALT) phenotype and when they looked at a variety of tumors, 
they found that this phenotype as well as the inactivating mutations in ATRX were 
present in tumors of the CNS (42).  Though there have been no mechanistic studies 
proving definitively that mutations in ATRX cause ALT, the association in our studies 
and many others have shown it to be incredibly tight with as many as 49 out of 50 ATRX 
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mutated tumors displaying the ALT phenotype and out of 21 gliomas with ATRX intact, 
zero exhibited the ALT phenotype(35).   
We sought to define the mutation status of these genes in complement with the 
mutation status of IDH1 and IDH2 with the goal of classifying the various subtypes of 
gliomas.  To this end, we analyzed the loci of 363 brain tumors consisting of 203 
astrocytic tumors of varying grade, 50 oligodendrogliomas of varying grade, 40 
oligoastrocytomas (mixed tumors displaying characteristics of both astrocytomas and 
oligodendrogliomas), as well as 5 Grade II ependymomas, and 65 Grade IV 
medulloblastomas.   
We observed frequent occurrence of mutations in ATRX in the astrocytic subset 
of gliomas including Grade II astrocytomas (67%), Grade III astrocytomas (73%), 
secondary GBMs (Grade IV, 57%), and in the mixed oligoastrocytomas (68%).  This was 
in contrast to those ATRX mutations observed in primary GBMs (4%) and 
oligodendrogliomas (14%).  ATRX most commonly harbored frameshift mutations or 
nonsense mutations leading to a truncated protein, which together accounted for 91% of 
the mutations observed.   
The association between alterations in ATRX and other mutations was assessed 
and it was found that 99% of those tumors harboring ATRX mutations also displayed 
mutations in IDH1 or IDH2.  94% of these same tumors also contained mutations in 
TP53.  This data offers the genetic landscape for astrocytomas, a signature that has been 
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validated several times since this publication through our own published work as well 
as others (Figure 4)(36,37,43,44).   
A further correlation that was observed was in assessing those tumors that displayed the 
ALT phenotype.  ALT is an alternative means of immortalization that relies on 
homologous recombination, and thus stabilization of the telomeric regions.  This allows 
the cells to divide indefinitely without encountering the end-replication problem.  ALT 
occurs in the minority of cancers, only about 15%, whereas the majority of cancers and 
immortalized cells induce expression of telomerase, an enzymatic based mechanism for 
telomere maintenance and circumvention of the end-replication problem(45).  It has 
been shown that astrocytomas in particular tend to have ALT, however not 
oligodendrogliomas(46,47).  In our studies, we show that there is an incredibly tight 
association between mutations in ATRX and the ALT phenotype, to the extent that 100% 
of gliomas that had the ALT phenotype also had mutations in ATRX.  Additionally, 
neither the ALT phenotype nor mutations in ATRX were observed in the 
oligodendrogliomas.  The link between ATRX mutations and ALT has been reported 
several times now, however there is a lack of functional data supporting a mechanism 
for how ATRX loss-of-function induces ALT. 
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Figure 4:  Genetic landscape of gliomas 
Distribution of mutations in ATRX, TP53, IDH (IDH1 or IDH2), CIC, FUBP1, and chromosomal loss of 1p/19q among 
gliomas show signatures specific for each type of glioma. ATRX, TP53, and IDH display a co-mutated status among the 
astrocytomas of Grade II, III, and secondary Grade IV.  This is in contrast to the Grade II and Grade III oligodendrogliomas that 
show mutations in FUBP1 and CIC as well as chromosomal loss of 1p/19q.  Oligoastrocytomas present with mutations in either 
IDH, ATRX, and TP53 or in IDH, and FUBP1 or CIC, or with loss of 1p/19q, suggesting that though tumors appear mixed 
histologically, genetically these tumors have the signature of either astrocytoma or oligodendroglioma, but not both.  Also shown 
is the mutation spectrum of primary GBM showing it is genetically distinct disease.  Note: cells shaded in gray indicate no data 
was available for those samples.
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The presence of mutations in CIC and FUBP1 were also determined and found to 
occur in the Grade II (38% and 14%, respectively) and Grade III (52% and 31%, 
respectively) oligodendrogliomas.  This occurrence was in contrast to the presence of 
these mutations in primary GBMs, which was 1% and 2%, respectively.  Interestingly, 
these mutations were completely absent (0%) in the Grade II and Grade III astrocytic 
tumors.  In all cases where there were mutations in CIC or FUBP1, IDH1 or IDH2 was 
mutated, and were found to also co-occur with chromosomal loss of 1p/19q.  This data 
offers the genetic landscape for oligodendrogliomas (Figure 4). 
The survival data for the different glioma subtypes is consistent with what is 
expected based on histopathological diagnosis alone.  Those patients harboring 
mutations in IDH1 or IDH2 and in ATRX typically have astrocytomas.  These patients 
have a median survival of 51 months.  Those patients with mutations in IDH1 or IDH2 
and CIC or FUBP1 typically have oligodendrogliomas and have a median survival of 96 
months.  Lastly, those patients with primary GBM, who tend to not have mutations in 
any of the above genes, tend to have the worst prognosis, with a median survival of 13 
months.  In all cases, those patients who had mutations in IDH1 or IDH2 had a better 
survival then in those patients without mutations.  This has been reported several times 
and is a consistent finding, however little is known as to the etiology of IDH1 mutant 
tumors and how they confer a survival advantage(24,25,35-37,48). 
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The genetic signatures we have identified are capable of distinguishing between 
oligodendrogliomas, astrocytomas, oligoastrocytomas, as well as primary and secondary 
GBMs.  Primary and secondary GBMs have conferred tremendous difficulties to the 
neuropathologist as they are histologically very similar with few, if any distinguishing 
features other than secondary GBMs arising from preceding lesions.  Our genetic profile 
for these tumors complements the traditional histology-based means of diagnosis for 
these diseases.  Additionally, the ability to perform sequencing-based diagnosis is a cost-
effective and efficient alternative that comprises an inherently unbiased approach to 
diagnosis.  This can help resolve the issue of inter-institutional discrepancies in 
histological diagnosis of the same samples.  Promoting consistent diagnoses will 
comparably aid in consistent therapeutic intervention, likely contributing to enhanced 
survival. 
2.3  Mutant IDH1 in tumorigenesis 
In addition to gliomas, mutations in IDH1 and IDH2 have been detected in 
chondrosarcoma, enchondroma, Ollier disease and Maffuci syndrome, intrahepatic 
cholangiocarcinoma, a small percentage of prostate cancer, angioimmunoblastic T-cell 
lymphoma, and acute myeloid leukemia (AML), among others(49-56).  The high 
incidence of mutations in IDH1 and IDH2 in gliomas, together with them being mutated 
in such a variety of other cancers strongly implicates the involvement of these mutated 
genes in disease initiation and development.  A precise and specific mechanism for how 
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mutant IDH1 and IDH2 solicits its effects are unknown, however there are no shortage 
of publications speculating and offering some convincing data toward particular 
mechanisms.  Due to IDH1’s promiscuous activity throughout a cell, the mechanism by 
which mutant IDH1 imparts its tumorigenic activity is likely a convergence of various 
perturbed intracellular pathways.  The pathways that mutant IDH1 and 2-HG have been 
implicated in or suspected of having an effect on are summarized in Figure 5. 
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Figure 5:  Mutant IDH1 and 2-HG signaling pathways. 
The metabolic product of mutant IDH1 (and mutant IDH2) alters a number of 
downstream cellular activities that could be implicated in tumor development and 
progression.  2-HG competitively inhibits α-KG binding to several histone 
demethylases, leading to aberrant histone modification.  2-HG also inhibits TET2 
hydroxymethylases, decreasing levels of 5-hmC and perturbing methylation patterns.  
Subsequent effects on regulation of gene expression have been observed.  It can be 
reasoned that 2-HG also leads to increased VEGF signaling through stabilization of 
Hif1α, leading to increased angiogenesis though this is controversial with conflicting 
data.  Reprinted by permission from Macmillan Publishers Ltd: Nature Publishing 
Group as described in Appendix A(57). 
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2.3.1  Biology and biochemistry of mutant IDH1 
From its discovery, determining the effects of mutant IDH1 on cells has been an 
active pursuit of investigation.  Conflicting results have arisen in terms of mutant 
IDH1’s effects on basic cellular processes including cell proliferation and ability to form 
colonies in soft agar.  Studies utilizing immortalized human astrocytes infected with 
either IDH1-R132H or IDH1-WT found that mutant cells acquired a proliferative 
advantage over wildtype and also acquired the ability to form colonies in soft agar(58).  
It was noted that this phenotype required upwards of 14 passages in order to become 
apparent.  Another study has shown that expression of mutant IDH1 actually confers a 
negative impact on cell proliferation in vitro and in vivo(59).  In this study, Bralten et al., 
utilized established glioma cell lines and overexpressed either wildtype or mutant IDH1.  
A marked decrease was observed in those mutant IDH1 expressing cell lines.  This was 
corroborated when the cells were injected intracranially into mice.  Tumors that 
developed from mutant lines displayed decreased proliferation, altered migration, as 
well as prolonged survival (40.3 days for mice injected with mutant IDH1 expressing 
cells versus 29 days for mice injected with wildtype IDH1 expressing cells)(59).  There 
were no observable differences in apoptosis in these cells, suggesting that the cells were 
able to persist despite high production of 2-HG.  To elucidate whether this phenotype 
was specifically due to the production of 2-HG, they treated wildtype cells with 
supernatant containing 2-HG and recapitulated their in vitro data, suggesting the 
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reduction in proliferation is at least in part due to accumulation of 2-HG.  The effects of 
mutant IDH1 on cell proliferation can be a cell context-dependent phenomenon.  
However, considering the difficulties in propagating patient derived cell lines and 
xenografts harboring mutant IDH1, it is very plausible that mutant IDH1 alone may not 
display an aggressive tumorigenic phenotype that we observe in human disease without 
the incorporation of additional mutagenic hits(60,61).   
There have been several studies investigating the biochemistry of isocitrate 
dehydrogenase (IDH).  IDH functions as a homodimer with each homolog comprising a 
large domain, clasp domain, and a small domain that interact to expose the active site to 
substrate.  IDH1 transitions between an inactive open, an inactive semi-open, and a 
catalytically active closed conformation(28).  Mutations in humans always present in a 
heterozygous state which promotes the formation of wildtype:wildtype homodimers, 
mutant:mutant homodimers, as well as mutant:wildtype heterodimers, the latter of 
which were found to produce α-KG much less efficiently than their wildtype 
homodimer counterpart , however were able to reduce it to 2-HG(29,62).  This leads to 
the question whether mutant IDH1 confers dominant negative activity.  To address this, 
NADP+ activity was assayed in a human oligodendroglial cell line that overexpressed 
wildtype or mutant IDH1 that were FLAG-MYC tagged in the presence of the isocitrate 
substrate.  These studies showed that mutant:wildtype heterodimers had a significantly 
lower reaction rate than wildtype:wildtype homodimers.  Wildtype IDH1 
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overexpression lead to an increase in NADP+ in lysate, however in mutant lines, there 
was little effect on this activity showing that mutant IDH1 does not dominantly inhibit 
wildtype activity and it must be eliciting its tumorigenic effects in ways other than 
affecting wildtype biochemistry directly(63). 
The data supplied by the TCGA has been a huge resource(23).  Building from this 
work and expanding into gene expression analysis, Verhaak et al., generated a robust 
gene expression-based molecular classification system of GBM that has been an equally 
valuable resource to compare and assess faithfulness of cell lines and xenografts to 
human disease(38).  In this classification, GBM is divided into Proneural, Neural, 
Classical, and Mesenchymal subtypes, each one corresponding to a unique gene 
expression profile.  Briefly, the Classical subtype contained amplifications of 
chromosome 7 that was paired with loss of chromosome 10 in addition to amplification 
of EGFR and lack of mutations in TP53.  The neural stem cell marker NES as well as 
Notch, and Sonic hedgehog pathways are expressed in this subtype.  The Mesenchymal 
subtype consisted of loss of region 17q11.2, mutations in and low expression of NF1, as 
well as higher expression of mesenchymal markers including CHI3L1 and MET.  The 
Proneural subtype displayed alterations in PDGFRA and IDH1, and concurrent 
mutations in TP53.  This group showed high expression of oligodendrocytic 
developmental genes including PDGFRA, NKX2-2, and OLIG2.  Several proneural 
developmental genes were activated in this class such as SOX genes, DCX, DLL3, ACL1, 
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and TCF4.  Lastly, the Neural subgroup exhibited expression of neuron markers 
including NEFL, GABRA1, SYT1, and SLC12A5.   
Subsequent studies looking at DNA methylation profiles of GBMs and low-grade 
gliomas found that there was a distinct subgroup of gliomas that displayed a unique 
methylation profile enriched in the CpG islands of a subset of genomic loci(64).  This 
profile was termed the Glioma CpG Island Methylator Phenotype (G-CIMP), a 
phenotype that has been observed and characterized in other cancers including 
colorectal cancer(65).  87.5% of those gliomas that displayed G-CIMP were found to be 
categorized in the Proneural subgroup.  Additionally, those patients with G-CIMP 
tumors tended to be diagnosed at an earlier age and had a more favorable prognosis.  
These are all reminiscent of the features attributed to patients with mutations in IDH1 
and in fact, there was tight association between G-CIMP and mutations in IDH1. 
Promoter CpG island hypermethylation generally results in transcriptional 
silencing of associated genes and in fact, several of the hypermethylated foci in these 
samples included markers of mesenchyme, tumor invasion, and extracellular matrix, all 
of which were found to be downregulated when looking at gene expression patterns in 
these samples(64).  Interestingly, the Mesenchymal subgroup of gliomas displays a more 
aggressive phenotype, whereas the Proneural subgroup tend to exhibit a more favorable 
prognosis, suggesting that this more aggressive nature may be due to induction of a 
mesenchymal gene pattern due to the silencing of particular gene sets. 
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Several studies, including from our own lab, have sought to assess the 
contribution of mutant IDH1 and determine a causal effect for G-CIMP.  By either 
expressing mutant IDH1 in human astrocytes, or generating isogenic cell lines 
incorporating the IDH1-R132H mutation, it was found that mutant IDH1 is responsible 
for remodeling the methylome and inducing G-CIMP(66,67).  Additionally, it was found 
that the gene expression profile for mutant IDH1 expressing immortalized human 
astrocytes was similar to the profile found in low-grade gliomas suggesting these in vitro 
lines are faithfully recapitulating the expression patterns observed in human disease(66). 
2.3.2  2-HG inhibits α-KG dependent dioxygenases 
Determining a mechanism for the G-CIMP and the subsequent gene expression 
changes observed in IDH1-mutated gliomas required a closer examination of the 
biochemistry of the enzyme.  As mentioned previously, mutant IDH1 confers both a 
loss-of-function as well as a gain-of-function.  It has been reported that there is a 
reduction of α-KG to produce high levels of 2-HG(29).  Structurally, these products are 
nearly identical except at the C2 location; where in α-KG there is a carbonyl group, this 
is replaced with a hydroxyl group in 2-HG (Figure 2)(68).  Considering the high levels of 
2-HG present, it is highly suspected that this molecule that is nearly identical to α-KG 
will competitively inhibit the class of enzymes that is dependent on α-KG as a substrate 
for their activity, that is the α-KG dependent dioxygenases.  In fact, though it is shown 
that 2-HG is a relatively weak antagonist of α-KG, it is capable of perturbing the 
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function of many α-KG dependent dioxygenases especially when at high levels, such as 
the case is in IDH1 mutant tumors(68-73).   
According to the GenBank DNA database, there are approximately 70 known 
and putative α-KG dependent dioxygenases that could be compromised by elevated 
levels of 2-HG.  Their effects range in scope from epigenetic regulation and gene 
expression to implications in angiogenesis and tumor aggressiveness(72).  Specifically, 
those that have received the most attention with regard to being affected in IDH1 
mutated cells are the Ten-Eleven Translocation (TET) proteins involved in DNA 
methylation, the Jumonji-C domain-containing histone demethylases, and the prolyl 
hydroxylases regulating hypoxia-inducible factor (HIF) signaling.  
2.3.2.1  Ten-Eleven Translocation proteins and 5-hydroxymethylcytosine in glioma 
It turns out that both DNA methylation and histone methylation, two facets of 
epigenetic regulation affecting gene expression, are controlled by α-KG dependent 
dioxygenases.  The role that 2-HG plays in effecting these α-KG dependent 
dioxygenases is an active pursuit of research.   
The TET family of proteins, including and specifically that which is produced 
from the TET2 gene, is involved in normal development as well as many diseases, 
including glioma and myeloid leukemias.  Interestingly, mutations in TET2 are mutually 
exclusive with mutations in IDH1 or IDH2, suggesting the two genes may have similar 
pathogenic roles.  The normal function of the TET proteins is to catalyze the conversion 
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of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC)(73).  It is suspected that 
this process is the first step in the pathway leading to the demethylation of cytosine 
residues, and thus is strongly implicated in processes of gene regulation throughout 
development.  In fact, it was observed that the expression and activity of the TET 
proteins decrease as the cells differentiate.   The subsequent effects were observed when 
looking at the promoter regions of embryonic stem (ES) cell specific genes where there 
was a reduction in 5hmC levels and an increase in the 5mC levels at ES cell specific 
loci(74).  However, as the cell differentiates, the opposite was observed, with 5hmC 
levels increasing and 5mC levels decreasing.  The observation that the 5hmC mark is 
enriched in promoters with the histone 3 lysine 27 trimethylation (H3K27me3) mark, a 
mark correlated with transcriptional silencing, and the histone 3 lysine 4 trimethylation 
(H3K4me3) mark, a mark correlated with transcriptional activity, suggests that 5hmC 
contributes to the poised chromatin signature found in developmentally regulated genes 
and may represent a major event in generating an active gene expression state of tissue-
specific genes(75,76).  It was additionally found that not only is 5hmC elevated in more 
differentiated cell types and less so in ES cells, but it was observed that these reduced 
levels of 5hmC also applies to cancer cells(77). 
Taking into account that mutant IDH1 induces G-CIMP, the hypermethylator 
phenotype, together with the findings of 2-HG inhibiting the TET family of proteins and 
subsequently affecting 5hmC and 5mC levels, suggests that mutations in IDH1 may 
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change the expression of a large subset of genes.  The fact that mutations tend to occur 
very early on in tumorigenesis may allow these cells to persist in a stem cell like state, 
thereby contributing to tumorigenesis. 
To this end, eloquent studies have been performed looking at the effects of 
mutant IDH proteins in the hematopoietic system and characterizing gene expression 
and methylation profiles.  These studies have further lead to the conclusion that the 
hypermethylator phenotype promotes a gene expression profile similar to immature or 
stem-like cells and can be induced through the inhibition of the TET family of proteins 
via 2-HG production(70).  Additionally, they show that these cells display a block to 
differentiation and an inability to differentiate through the myeloid lineage.  A block to 
differentiation has been observed in several other cell contexts including adipocytes, 
hepatocytes, cells of the hematopoietic system, as well as immortalized human 
astrocytes, lending credence to the notion that one of the main oncogenic activities of 
mutant IDH1 is that it confers a block to differentiation of cells, maintaining them in an 
immature state capable of proliferation(56,78,79). 
2.3.2.2  Mutant IDH1’s effects on histone methylation in gliomas 
In a series of studies looking at the ability of 2-HG to inhibit various α-KG 
dependent dioxygenases, it was found that one of the more potent inhibitions occurred 
in the family of histone demethylation proteins including Jumonji domain containing 2A 
(JMJD2A) and Jumonji C-domain containing histone demethylase (JmjC)(72,80).  The 
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family of histone demethylases plays an important role in epigenetic regulation of gene 
expression.  Histone methylation dictates the structure, conformation, and organization 
of chromatin with particular modifications conferring either transcriptionally active 
euchromatin (H3K4, H3K36, H3K79), or transcriptionally silent heterochromatin (H3K9, 
H3K27, H4K20)(72).  The balance between these modifications is dependent on the 
activity of histone methyltransferases and histone demethylases.  Disruption to this 
balance or mutations in these regulators inevitably effect gene expression and 
pathogenesis.  Mutant IDH1’s effects on histone methylation marks have been directly 
linked with production of 2-HG in various papers(69,78,80).  In general, it appears that 
mutant IDH1 confers an increase in overall histone methylation by perturbing the 
activity of histone demethylases via competitive inhibition with 2-HG.  For IDH1 mutant 
tumors, there appear to be an increase in the repressive H3K9me3 and H3K27me3 
marks, suggesting that mutant IDH1 may preferentially affect repressive 
modifications(67,78). 
Histone demethylases have been characterized as tumor suppressors in some 
contexts and oncogenes in other contexts.  This suggests that their effects overall are cell-
context dependent.  For IDH1 mutant tumors in particular, it will be important to 
investigate the particular loci that are differentially methylated in IDH1 mutant tumors 
compared to wildtype and determine their effects on the expression of those loci.  
Additionally, the histone methylation profile of cells of the CNS and of the suspected 
 39 
cell of origin, whether that is NSCs or OPCs or even more differentiated cell types 
would be imperative as mutant IDH1’s effects could yield conflicting results depending 
on the histone methylation profile and balance of transcriptionally active versus 
repressive modifications that are present in the founding cell population. 
2.3.2.3  Contradictory effects of 2-HG on HIF signaling  
Another member of the α-KG dependent dioxygenases that could be inhibited 
are the prolyl hydroxylases that regulate HIF signaling.  The prolyl hydroxylases 
normally hydroxylate the HIF1α and HIF2α proteins.  These hydroxylated proteins are 
then recognized and ubiquitinated by Von Hippel Lindau (VHL), a ubiquitin E3 ligase.  
These targeted proteins will subsequently undergo proteasomal degradation.  Under 
hypoxic conditions however, the prolyl hydroxylases are inefficient and unable to 
properly hydroxylate HIF1α and HIF2α.  As a result, these proteins dimerize with 
HIF1β and function as transcription factors that coordinate a response to hypoxia, 
inducing expression of a range of genes including those involved in metabolism, 
angiogenesis, and tumorigenesis. 
The data regarding 2-HGs effects on the prolyl hydroxylases and on HIF 
signaling has been contradictory.  This may suggest that its activity and subsequent 
effects may be cell-context dependent, or that there are other pathways involved, 
diminishing or counteracting expected results.  The fact that 2-HG has weak inhibition 
of HIF hydroxylases under experimental conditions suggests that this would likely not 
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lead to HIF pathway activation and induction of downstream gene expression.  
Additionally, it suggests this pathway may not be the predominant mechanism for 
pathogenesis(80).  It should be noted that when IDH1 is mutated however, 2-HG is 
produced at such an excessive level that this may inhibit or perturb this pathway more 
than what was observed in these studies.   
In vitro studies utilizing the established U87 glioblastoma cell line shows that 
when mutant IDH1 is ectopically expressed, there is an increase in HIF1α and an 
induction of downstream target genes including that of vascular endothelial growth factor 
(VEGF)(69,81).  When cells were treated with 2-HG, a comparable result was observed.  
Expanding these finding into an in vivo context, Zhao et al., quantified HIF1α via 
immunohistochemistry (IHC) and found that all tumors harboring mutations in IDH1 
displayed a statistically significant increase in those cells staining positive with 
HIF1α(81).  Together, these groups concluded that mutant IDH1, by means of 2-HG did 
in fact induce HIF1α through an inhibition of prolyl hydroxylases(69).  
As alluded to previously, that a major oncogenic contribution of mutant IDH1 
lies in its induction of HIF1α and activation of downstream target genes is a 
controversial topic.  To further assess the association between mutations in IDH1 and 
stabilization of HIF1α, Williams et al., analyzed 120 archived formalin-fixed paraffin 
embedded (FFPE) glioma samples and looked for association between HIF1α and the 
IDH1 mutation(82).  The observations from this study included that HIF1α was 
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expressed in a subset of cells that also expressed the mutant IDH1.  HIF1α was also 
present in areas of necrosis and perinecrotic tumor cells.  It was noted however, that 
there were areas where mutant IDH1 was strongly expressed but HIF1α was absent, 
therefore leading this group to conclude there is no relation between the expression of 
mutant IDH1 and HIF1α(82). 
Another group investigating mutant IDH1’s effects on HIF1α looked at the EglN 
prolyl 4-hydroxylase specifically, the enzyme that incorporates the hydroxyl groups on 
HIF1α and targets them for degradation.  However, in contrast to previous studies, they 
showed that when mutant IDH1 was expressed in immortalized human astrocytes, 
HIF1α activity was diminished and this was associated with a proliferative advantage 
and ability to grow in soft agar(58).  These studies showed that 2-HG actually promoted 
EglN1 activity, leading to hydroxylation and subsequent degradation of HIF1α.  This 
was associated with lower expression of HIF targets.  Additionally, these findings were 
validated in an isogenic cell line derived from a human colorectal cancer line(58).  
Moving into an in vivo context, this group analyzed the gene expression pattern in the 
TCGA’s Proneural subgroup of gliomas and found that the HIF response genes were 
diminished.  Perhaps consistent with this set of data is that characterization of mutant 
IDH1 gliomas show that they tend to display a lesser degree of necrosis as well as a 
nonsignificant trend toward less frequent occurrence of vascular abnormalities, both 
indicators of decreased HIF1α activity(62,83).  Considering necrosis and vascularization 
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are usually markers for a worse prognosis, speculative but consistent thinking in this 
direction would imply that due to the lesser extent of necrosis and the less frequent 
vascular aberrations, together with the survival advantage that mutant IDH1 glioma 
patients display, that there may be justification for HIF1α being diminished in mutant 
IDH1 gliomas. 
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3.  Introduction:  Mice as a model organism 
Whether it is yeast, Drosophila, zebrafish, mouse, non-human primate, or any 
other model system, the contribution of these organisms to biomedical research cannot 
be understated or undervalued as their impact on human and animal health has been 
extraordinary.  Inevitably, due to their small size, ease of handling and housing, short 
generation times, ability for genetic manipulation, and perhaps most importantly, the 
fact that they share about 99% of their genes with humans with extensive homology, 
makes the mouse one of the more commonly utilized model organisms.  With genetic 
and physiological similarities to humans, the mouse can be used to scrutinize many 
physiological complexities including that of the immune, endocrine, nervous, 
cardiovascular, and skeletal systems.  Additionally, mice tend to naturally develop 
many diseases that affect humans such as cancer, atherosclerosis, hypertension, diabetes, 
osteoporosis, and glaucoma thus making the investigation of such diseases in these 
animals particularly relevant with most definitely many of the same causative molecular 
perturbations occurring.  For this reason, investigation of therapeutics targeting these 
naturally occurring diseases would be expected and have been shown to have similar 
biological consequences in mouse and human.  Lastly, for those diseases that arise in 
humans but not mouse, through manipulation of their genome or environment, many 
diseases can be simulated and induced including such diseases as cystic fibrosis and 
Alzheimer’s.  This together with the ability to control for such factors as environmental 
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contributions or variation among animals is another reason why mouse modeling is so 
advantageous and thus prevalent. 
Animal research has been the foundation for countless successes in the medical 
and public health arena, and we as humans have blindly reaped the benefits.  The 
elimination of Poliomyelitis as a public health threat, eradication of smallpox, 
understanding the genetic and environmental causative factors of cancer, vaccination 
and immunization against typhus, diphtheria, whooping cough, and tetanus are but a 
few of the major accomplishments that have animal research at its foundation.  Perhaps 
one of the most profound examples for how animal research has impacted human life is 
in the studies lead by Professor Pier Paolo Pandolfi of Harvard Medical School.  Early in 
his career, he discovered the genetic mutations responsible for acute promyelocytic 
leukemia (APL), a cancer of the bone marrow most common in younger people.  Being 
incredibly difficult to treat, most patients succumbed to the disease.  Through the 
generation of genetically engineered mouse models (GEMMs) and faithfully 
recapitulating the human disease in mouse, Pandolfi and colleagues were able to 
generate targeted therapies and now, the majority of patients survive.  A similar 
progression of events was displayed for the childhood leukemia, acute lymphoblastic 
leukemia (ALL).  The majority of the research for this disease took place at the St. Jude 
Children’s Research Hospital and at the time of its first investigation in 1962, survival 
was in the realm of 4%.  Now, survival is upwards of 90%.  To conclude, the impact and 
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necessity of animal research on human health and survival is invaluable and we have 
much of our health, well-being, and ability to overcome disease and sickness to our 
fellow animal counterparts. 
3.1  Mouse models of glioma 
As mentioned previously, mouse models have contributed significantly to the 
understanding of human disease.  Animal models complement other laboratory 
techniques to provide a resource that permits the dissection of molecular pathways, 
allowing for the construction of a roadmap for pathogenesis.  Additionally, pending 
pathogenesis is comparable with that of human disease, as is the ultimate goal, these 
resources provide a means for investigation of the most effective and impactful 
therapeutic modalities.   
Animal modeling is one of the few ways to fully recapitulate human 
tumorigenesis and to achieve a comprehensive understanding of tumor development as 
it encompasses many of the variables and components of human disease from 
physiology, microenvironment, impact of the immune system, tissue and cellular-
context, genomic contribution, and environmental components.  Several different 
techniques are employed to generate mouse models of tumorigenesis including chemical 
mutagen-induced tumorigenesis, xenograft transplantations, germline genetic 
modifications, and somatic genetic modifications.  Perhaps the most common for glioma 
modeling in particular are xenograft transplantations, germline genetic modifications, 
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and somatic genetic modifications, each presenting with their own advantages and 
limitations.  Ultimately, the system that encompasses the sequencing data from large-
scale genomic studies to assess the contribution and significance of particular mutations, 
combined with the ability to promote tumorigenesis in an orthotopic manner as to 
preserve the microenvironment and signals from within, as well as depicting the 
heterogeneity observed in patient tumors, and to do so with high penetrance and short 
latency will be the most impactful of models.  In doing so, the model generated will 
provide the most stable foundation for preclinical data acquisition. 
3.1.2  Xenografts as a model for glioma 
Xenograft models entail the injection of human tumor cells into a mouse, either 
into the flank region or intracranially, and commonly utilize immune-compromised 
animals.  This approach is utilized when a better understanding of the contribution of 
different genetic aberrations is desired.  For example, by incorporating different 
mutations and generating sub-lines of the parental line, one could determine the 
contribution these mutations are having on cell proliferation, migration, aggressiveness, 
and metastasis in vivo.  A representative experiment comes from Martens et al., where 
several GBM xenografts were engrafted.  Infiltration into surrounding brain 
parenchyma, proliferation, and response to therapy were found to be dependent on the 
mutation spectrum of each GBM, specifically with regard to the presence of EGFR 
amplification(84).  In addition to these biologically faithful systems allowing for an in 
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depth analysis of tumor development and progression, much of the power for xenograft 
systems lies in the investigation of therapeutic modalities to assess the most effective 
interventions and protocols for tumor regression.  In many instances, the use of 
xenografts faithfully recapitulates the histological appearance and subtyping of the 
parental tumor of which the cell line was derived as well as the gene expression 
profiles(85-88).  These features must be validated and ensured in each instance as there 
are most definitely cases where biology, genetics, or histology are lost, leading to a 
fundamental failure of the system with regard to relevance(89).  For xenografts in 
particular, it has been difficult to fully recapitulate the primary human lesion as once 
transplanted into the mouse, the cells form well-demarcated and compact lesions as 
opposed to the diffusely infiltrative nature of the disease that is inherent of human 
gliomas.  Oftentimes, xenografts require injection into immune-compromised animals, 
and with ever increasing data suggesting the importance of the immune system in 
shaping tumor progression and response to therapy, this imparts a major drawback.  
Additionally, the ability to generate the human derived xenograft and recapitulate the 
human disease in vivo are among the hurdles to be overcome in xenograft modeling.  
This is especially true for the study of IDH1 mutated gliomas which are known for being 
incredibly difficult to culture in vitro as well as for xenograft establishment(61).  
Interestingly, it has been reported that xenografts tend to graft and display much more 
of an aggressive phenotype when they are derived from a higher-grade tumor(90).  
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Perhaps one of the difficulties in propagating mutant IDH1 cell lines and xenografts lie 
in that they tend to occur in those tumors of lower grade, including the Grade II and 
Grade III tumors. 
3.1.3  Somatic gene transfer and the study of gliomagenesis 
Xenografts, being derived from human samples, often display genetic 
heterogeneity both as a result of therapy that the patient has endured as well as a result 
of the in vitro culturing of the cells.  When injecting these cells into mice, the precise role 
of particular genes and how they are interacting with the products of other genetic 
perturbations is unknown; similarly, the relevance to initiation, development, or 
maintenance of the human tumor is unknown.  To this end, other modeling systems 
including somatic gene transfer, offer advantages.  One system for gene transfer that has 
been particularly fruitful has utilized replication-competent avian sarcoma-leukosis 
virus long terminal repeat with splice acceptor (RCAS) vectors that permit the transfer of 
genes into transgenic mice expressing t-va, the avian receptor for RCAS(91,92).  In this 
way, through the injection of either virus or virus producing avian-derived cells, genes 
of interest can be incorporated into cells or tissues that express the viral receptor.  As 
mammalian cells do not express t-va, off target infection or gene introduction into cell 
types other than those in which t-va is being expressed in is thus avoided.  An ever-
expanding cohort of tv-a mice is being generated, however the most common ones for 
glioma modeling include those in which tv-a is expressed under control of neural 
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specific promoters, such as Nestin expressed in the progenitor compartment, or GFAP 
expressed in mature astrocytes and some progenitor cells of the SVZ, among others(89). 
There are several advantages in using the RCAS/t-va system.  For one, this 
system can be used to interrogate the cell of origin by determining the susceptibility of 
particular cell types to transformation.  Additionally, the same cells can be infected with 
multiple viruses at the same time.  Therefore, the cooperation of several genetic 
mutations can be investigated.  Likewise, you can infect sequentially with different 
viruses to determine the initiation or maintenance contribution of particular mutations.  
One drawback for this system is that these viruses can only package genes of certain 
size; a rough rule is to clone in genes less than 2.5-kilobases.  Though many genes are 
smaller than this, there are some that will be unable to be replicated due to size.  
Another limitation is with regard to the difficulty of incorporating mutations that 
present as deletions, knock-downs, or tumor suppressors.  To overcome this, these mice 
can be crossed to other transgenic animals, including those of tumor suppressor-
deficient backgrounds.  Crossing to conditional transgenics further adds to the utility of 
this system as transfer of virus encoding Cre-recombinase can selectively activate or 
delete genes from t-va expressing cells that are infected.  The fact that these animals are 
immune-competent provides the advantage of an intact immune system in terms of 
modeling and providing a relevant microenvironment.  However, this can complicate 
injections into adult animals as inflammation and an immune response can ensue, 
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though it has been shown that tumors, specifically GBMs can be induced in adult 
animals(91). 
One of several landmark studies shows the utility of the RCAS/t-va system while 
also showing the importance of different locations and thus microenvironments, on the 
tumor initiating ability of different oncogenes(91).  In this study, Hambardzumyan et al., 
show that PDGFB can drive gliomagenesis in the SVZ, cortex, and the cerebellum 
suggesting that there are different cell populations throughout the adult brain that are 
capable of tumor formation.  The same system can also be used to investigate the 
contribution of genetic background to tumorigenesis, scrutinize the identity of the cell of 
origin, or even assess the response to different therapeutics in adult gliomas. 
3.1.4  Genetically engineered mouse models of gliomagenesis 
GEMMs are the gold standard for modeling for many reasons.  Not only can 
GEMMs be generated to incorporate the exact mutations found in human samples, but 
they can be induced to express these mutations in a tissue-specific manner at a 
designated time, thereby achieving spatio-temporal control that can be as restricted or as 
broad as the promoter in which one is using.  This is accomplished through the 
incorporation of the Cre/LoxP system whereby the Cre-recombinase recognizes 34-base 
pair DNA sequences artificially and intentionally incorporated into the genome.  These 
sites will undergo recombination and excise the intervening genomic sequence.  There 
are many possibilities for how best to use this technology, however some include 
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incorporation of reporters to know when a particular gene is being recombined or 
expressed, or expression of Cre-recombinase could induce excision of a stop cassette that 
was silencing an oncogene, thereby promoting its tumorigenic activity.  Alternatively, 
the LoxP sites can be placed such that they are located at critical regions of the gene, 
perhaps flanking the exons required for catalytic activity, and thus upon expression of 
Cre-recombinase and excision of the intervening sequence, the gene will be knocked-out.  
To add an additional level of control, Cre-recombinase can be induced under control of 
different promoters, thereby expressing Cre-recombinase and inducing either the 
activity of an oncogene or knocking out a gene in a tissue-specific manner, depending on 
what tissues the promoter is expressed in.  Temporal regulation can also be achieved 
through the use of an inducible Cre-recombinase.  In this case, Cre-recombinase is fused 
to a mutated hormone-binding domain of the estrogen receptor, ERT2.  It is only when 
the estrogen analog is administered that the Cre-recombinase is translocated to the 
nucleus where it can act on the LoxP sites and induce recombination at the sites.  When 
the CreERT2 is fused to a particular promoter, tamoxifen administration will induce the 
translocation of the recombinase to the nucleus in only those cells in which the promoter 
is active.  In this way, one can achieve spatio-temporal control of gene deletion or 
oncogene activation.  This allows for the investigation of the induction of different 
mutations at different stages of development.  Additionally, through crossing with other 
strains of GEMMs, several mutations can be incorporated and induced within the same 
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cell, thereby allowing for the study of cooperativity among genetic mutations found in 
humans.   
The generation of GEMMs and the conditional expression system alleviates 
many issues that arise in mouse modeling.  Many times certain mutations either confer 
adverse effects or can be embryonic lethal to the animals.  Spatio-temporal control over 
the induction of these mutations allows for these events to be overcome, permitting 
study of critical genes without the animal succumbing.  Additionally, as these mutations 
are induced in the particular cell of interest, it is unlikely that other mutations will 
accrue.  Therefore, the genetic stability is something that can be controlled, unlike in 
xenograft models.   In theory, there should be no loss or gain of known or unknown 
genetic alterations as there is no process of in vitro culture or previous history of therapy.  
GEMMs do have intact immune systems and thus offer a more realistic and faithful 
microenvironment.  This is advantageous for tumor growth as it promotes the 
appropriate interaction and signaling between tumor cells and the stroma.  This is an 
ideal situation as it recapitulates the biology of a naturally occurring tumor and 
promotes the study of the cooperativity and interaction of these cells on the initiation, 
development, and progression of the tumor over time, as well the study of the 
regression of the tumor following therapeutic intervention.  One drawback of GEMMs is 
that they cost more to generate compared to other model systems.  Additionally, tumor 
development can be a slow process that is dependent on both the potency of the 
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mutation as well as the promoter in which it is being expressed.  Though the refinement 
of expression is an advantage, it can also be a daunting task to determine the precise 
time, location, and cell type to induce expression of the particular mutation.   
One of several examples of mouse glioma models that demonstrate the 
physiological relevance and value of GEMMs for future preclinical studies lies in a study 
by Reilly et al., where animals with mutations in NF1 and TP53 were crossed and found 
to develop a range of brain lesions including diffuse cells with atypical nuclei to large, 
aggressive tumors bearing several histological hallmarks(93).  For example, some tumors 
presented with elongated astrocytic nuclei with irregular contours (diffuse astrocytoma, 
Grade II), while others displayed increased mitotic activity (anaplastic astrocytoma, 
Grade III).  A subset also exhibited focal tumor masses, areas of necrosis, and even 
multinucleated giant cells (GBM, Grade IV).  The fact that these tumors were generated 
in vivo, in a context with known genetic aberrations, without incorporating exogenous 
means of mutagenesis proves that this controlled system permits the study of particular 
genetic anomalies and is able to generate histologically faithful tumors that recapitulate 
the biology of human disease.   
Harnessing the wealth of genetic sequencing data for human tumors, together 
with the determination of the genetic signatures of the family of gliomas, we were 
poised to generate genetically faithful mouse models that encompass those mutations 
and perturbed core signaling pathways that are most commonly found in human 
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gliomas.  Our goal was to generate models that accurately reflect progressive gliomas 
and can be used to advance our understanding of the disease while producing a 
platform for preclinical testing of new treatment options. 
 
3.2  Generation of a mutant IDH1 conditional knock-in mouse 
model 
Our goal was to generate genetically faithful mouse models that harbor those 
precise mutations most commonly found in human progressive glioma.  These include 
mutations in IDH1, ATRX, and TP53 (Figure 4)(35,36).  As GEMMs have already been 
generated for conditional deletion of ATRX and TP53, we sought to generate the first 
mouse model permitting the conditional expression of mutant IDH1, specifically one 
that expresses the most common mutation found in human gliomas, the R132H 
mutation(25,94,95).  To fully recapitulate the mutation spectrum observed in human 
glioma, particularly the astrocytic subset of glioma, these newly generated mice will be 
crossed with previously generated animals incorporating conditional deletion of ATRX 
and conditional deletion of TP53(94,95).  These studies allowed us to answer what the 
effects of these mutations are on specific cell types of the brain including the neural stem 
cells.  The generation of these animals also allows for the understanding of why these 
genes are so commonly found to be co-mutated in human gliomas as well as provide a 
means for assessing the most effective therapeutics.  Additionally, because IDH1 is 
found to be mutated in so many other cancers and diseases, the models generated from 
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these studies will exhibit broad application and will lend insight into pathogenesis of 
these many other cancers and diseases(49-56). 
Generation of the mutant IDH1 conditional knock-in mouse model was done in 
collaboration with the University of North Carolina School of Medicine Animal Models 
Core Facility.  For this process, a targeting vector was constructed based off of the 
genomic sequence of the 129P2/Ola strain of mouse.  The targeting construct contained 
the following features: a 5,426-base pair 5’ homology arm encompassing exon 2 of IDH1 
followed by a LoxP site, three copies of the SV40 polyadenylation signal, a neomycin 
resistance gene flanked with FRT sites, another LoxP site, and a 2,416-base pair 3’ 
homology arm encompassing exon 3 of IDH1 and the R132H mutation (Figure 6A).  In 
humans, the arginine-132 residue of IDH1 is encoded by a CGT codon and is most 
commonly mutated to histidine, CAT.  The construct generated for these studies targets 
the endogenous mouse locus, requiring a two-base pair change from the CGA codon for 
arginine to the CAC codon for histidine.  This targeting construct was electroporated 
into 129P2/Ola mouse ES cells and recombinants were selected using G418.  Polymerase-
chain reaction (PCR) across the 3’ homology arm was performed to distinguish 
homologous recombinants from non-homologous integrants.  16 clones gave a positive 
signal, of which 8 were chosen for Southern blot analysis to confirm the homologous 
targeting.  Briefly, genomic DNA was digested with the SacI restriction endonuclease.  
When the wildtype allele is present, this would liberate a 16.1-kilobase fragment that 
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could be detected through one of two probes, either a 5’ or a 3’ probe.  Alternatively, 
when the mutant allele is present, an 8.8-kilobase fragment and a 10.3-kilobase fragment 
will result, each being detected by the 5’ or the 3’ probe, respectively.  Clones 1F4, 2E7, 
2F3, 3F1, 3G3, and 4E3 all displayed the 8.8 kilobase band indicating correct targeting 
(Figure 7A and B).  Two additional probes including the 3’ probe as well as an internal 
probe in the neomycin gene were used.  Though the 3’ probe and the neomycin probe 
showed similar results, the neomycin probe showed an extra band in clones 1F4, 2E7, 
and 2F3 suggesting that though there was proper integration, there was also a random 
integration site.  Further screening showed that clone 2E7 contained R132H and 
microinjection was performed into blastocysts derived from the C57Bl/6 mouse strain  
(Figure 7C).  2E7 went produced chimeras that gave germline transmission of the 
targeted allele.  Resultant chimeras derived from 2E7 were screened for germline 
transmission through PCR and sequencing based assays as will be described further in 
the next section. 
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Figure 6:  Generation of GEMMs. 
Animals with conditional expression or deletion of those genes most 
commonly mutated in the astrocytic subset of gliomas were generated or gifted.  (A) A 
floxed stop cassette upstream of the R132H mutation of IDH1 was incorporated to 
generate a conditional knock-in.  (B) Exon 18 of ATRX was floxed to generate a 
conditional null allele.  This was described previously(94).  (C) Exons 2 through 10 of 
TP53 were floxed to generate a conditional deletion.  This was described 
previously(95). 
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Figure 7:  Validation of IDH1-R132H incorporation into the genome. 
Molecular details of targeting strategy and validation for generation of IDH1-
R132H conditional knock-in include (A) Presence of SacI site in mutant allele such 
that upon digestion, mutant allele will have an 8.8-kb and a 10.3-kb band compared to 
the 16.1-kb band present in the wildtype allele when visualized through Southern 
blot.  (B) Southern blot using the 5’ probe shows 6 clones with successful integration.  
(C) Further screening shows of those 6 clones, 2E7 and 2F3 contain the CGA to CAC 
R132H mutation.  2E7 was microinjected and generated chimeras capable of germline 
transmission. 
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3.2.1  Validation of conditional knock-in IDH1-R132H mice 
Chimeras were generated and bred.  To ensure germline transmission and to 
maintain lines of conditional knock-in IDH1-R132H 129P2/Ola, PCR-based and 
sequencing-based assays were applied.  Genomic DNA (gDNA) was obtained from 
either tail snips of pre-weaned animals or toe-clips from postnatal day 9 (P9) animals.  In 
either case, the tissues underwent lysis, gDNA was extracted, and PCR and sequencing 
of gDNA was performed to validate the presence of the targeted allele (Appendix D and 
Materials and Methods).  Two pairs of PCR primers were made to amplify either the 
wildtype IDH1 allele or the targeted allele, generating a 329-base pair amplicon or a 263-
base pair amplicon, respectively (Figure 8).  Additionally, primers were generated that 
contained the M13(-20) forward primer to allow for efficient sequencing reactions that 
would amplify the mutated region allowing us to distinguish wildtype, mutant, and 
heterozygous animals based on the presence of the CGA or CAC codon, or a mixture of 
the two.  PCR results of all generated animals resulted in either a wildtype band and a 
targeted band or only the wildtype band, suggesting that our animals were in a 
heterozygous state.  Homozygous animals were never observed (Table 1).  In a series of 
62 crosses between IDH1-R132H/Wildtype (heterozygous) animals, 292 animals were 
generated with 113 Wildtype/Wildtype and 179 IDH1-R132H/Wildtype animals 
resulting.  Zero animals were IDH1-R132H/IDH1-R132H.  Performing a χ2 analysis to 
test for a 1:2:1 Mendelian inheritance pattern, we determined the χ2 value to be 102.35 
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with a P-value to be less than 0.0001, suggesting this was not due to chance.  
Additionally, failure to recover IDH1-R132H/IDH1-R132H animals (either due to 
embryonic or perinatal lethality) at the time of genotyping (P9) would subsequently 
generate a 1 to 2 ratio for Wildtype/Wildtype versus IDH1-R132H/Wildtype progeny, 
we derive a χ2 value of 3.75 and a P-value of 0.0528, suggesting that this hypothesis is 
plausible (Table 1).  Failure to generate IDH1-R132H/IDH1-R132H animals would not 
be surprising as the targeted allele is knocked-out due to the presence of the SV40 
polyadenylation signal that lies upstream of the R132H mutation.  Considering IDH1’s 
active role in metabolism and the TCA cycle, it is likely that homozygous animals are 
not viable.   
The presence of one wildtype allele and one targeted allele is ideal as once the 
stop cassette of the targeted allele is excised via expression of Cre-recombinase, this will 
generate a heterozygous state with one wildtype allele and one mutant allele, thus 
maintaining the genetically faithful and representative nature of our system as glioma 
patients present with heterozygous IDH1 mutations. 
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Figure 8:  Genotyping validation of IDH1-R132H animals. 
Genomic DNA was extracted from either tail-snips or toe-clips.  Primers 
specific for either the wildtype allele or the mutant allele are shown in (A).  (B)  
Wildtype allele will yield 329-basepair amplicon whereas mutant will yield 263-
basepair amplicon.  (C) Sequencing amplicons using primers containing the M13(-20) 
adaptor allow for efficient sequencing of the area spanning the mutation.  Animals 
either display the CGA codon for arginine or a combination of CGA and CAC for 
histidine, implying we generate either wildtype animals or heterozygous animals.  
Homozygosity of R132H was not observed. 
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Table 1:  Mendelian Genetic Assessment for Mutant IDH1 Animals. 
62 crosses yielding a total of 292 progeny were assessed.  Crosses were of 
IDH1-R132H/Wildtype with IDH1-R132H/Wildtype.  Expected ratios are shown in the 
top panel.  With a χ2 value 102.35 and a P-value of <0.0001 it is unlikely that the lack of 
homozygous mutant animals was due to chance and thus the hypothesis that the 
progeny followed a 1:2:1 Mendelian ratio was rejected.  The bottom panel shows a test 
for the hypothesis that there is a failure to recover animals that are homozygous 
mutant IDH1, and thus the expected progeny would follow a 1:2 ratio.  With a χ2 value 
of 3.8 and a P-value of 0.0528, the null hypothesis cannot be rejected and is thus a 
plausible explanation. 
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3.3  Insight from genetic signatures of gliomas to generate 
genetically faithful mouse models 
As we discovered, the genetic signature of the progressive gliomas, particularly 
the astrocytic subset, include mutations in IDH1, ATRX, and TP53 (Figure 4)(35,36).  
Having generated the conditional knock-in of IDH1-R132H, we next sought to 
incorporate those mutations that are co-mutated with IDH1.  Independent mouse 
models with conditional deletion of ATRX and TP53 have been generated previously 
and we have obtained these animals as gifts from the respective principle investigators 
(Figure 6)(94,95).   
3.3.1  Incorporation of conditional deletion of ATRX into genetic 
model 
ATRX was first identified as playing a causative role in ATRX syndrome, a 
severe, non-progressive type of X-linked mental retardation characterized by its 
association with an unusual form of α-thalassemia(96).  Fortunately, many functional 
studies of this huge gene encompassing 300-kilobases and 36 exons have been reported 
and the activities of the functional domains have been characterized(97-99).  ATRX 
contains two functional domains.  At the N-terminus is the ATRX-DNMT3-DNMT3L 
(ADD) domain.  This ADD has been shown to impart the ability to bind DNA to the 
protein.  In the C-terminus lies the helicase/adenosine triphosphatase (ATPase) domain, 
which is the enzymatic core of the protein and powers the activity of the protein(98).  In 
patients with ATRX syndrome, mutations tend to cluster in these two regions and the 
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same is observed in human gliomas, with mutations clustering within these 
domains(35,98).  These mutations are usually in the form of truncating (frameshift) or 
nonsense mutations (Figure 9). 
 
 
Figure 9:  Distribution of ATRX mutations. 
The coding sequence of ATRX is shown with the types mutations plotted 
against their location within the sequence (n=85).  Shaded triangles represent 
frameshift mutations, and shaded circles represent nonsense mutations, suggesting 
the majority of ATRX mutations observed in gliomas are truncating mutations.  Open 
circles represent missense mutations. 
 
The conditional knock-out ATRX animals contained a floxed neomycin resistance 
cassette within intron 17 and LoxP sites flanking exon 18 of endogenous ATRX (Figure 
6).  Upon expression of Cre-recombinase, this yields excision of exon 18, the catalytic 
domain of the protein, generating the functional equivalence of a null mutation(94).  
These animals were crossed with our conditional knock-in IDH1-R132H animals and a 
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PCR-based strategy for screening progeny was used to assess the presence of the 
targeting construct (Appendix D). 
3.3.2  Incorporation of conditional deletion of TP53 into genetic model 
Somatic mutations in TP53 are among the most frequent alterations identified in 
human cancers and are present in almost every type of cancer(100).  Normally, TP53 
functions as a tumor suppressor in its regulation of the cell cycle.  Though there are 
countless studies regarding the function of TP53 mutations in cancer, a general 
conclusion is that TP53 mutations are associated with changes in invasion and 
migration, genomic stability, angiogenesis, stem cell expansion, and apoptosis(101,102).  
In generating a conditional deletion of TP53, LoxP sites were integrated in intron 
1 and intron 10 such that upon expression of Cre-recombinase, the intervening sequence 
would be excised, and thus deleted (Figure 6)(95).  PCR was performed to screen 
progeny and identify the compound GEMMs (Appendix D and Materials and 
Methods).  In doing so, we created animals with conditional expression of mutant 
IDH1-R132H, as well as conditional deletion of ATRX and TP53, thereby generating the 
first compound genetic model harboring the most common mutations found in 
progressive glioma. 
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4.  Introduction:  Characterizing the effects of mutant 
IDH1 on the brains of GFAP-Cre; IDH1-R132H animals 
The IDH1-R132H conditional knock-in model is dependent on the expression of 
Cre-recombinase for the stop cassette to be excised and the mutant allele to be induced.  
This presents many avenues to pursue as there are many strains of mouse that have Cre-
recombinase expressed under control of different tissue-specific promoters.  The 
flexibility our system provides offers a great deal of potential.  With the frequency of 
IDH1 mutations in several different cancers and diseases, together with the ability for 
tissue-specific expression utilizing the diversity of available Cre-drivers allows us to best 
understand mutant IDH1’s role in pathogenesis in a cell-context-dependent manner.  
For our studies in particular, being focused on brain tumorigenesis, we were interested 
in expressing mutant IDH1 and its associated mutations in cells of the brain.   
Initial studies involved crossing our IDH1-R132H animals to a strain of mouse 
that has Cre-recombinase expressed under control of the human GFAP (hGFAP) 
promoter.  This gene encodes glial fibrillary acidic protein, an intermediate filament 
protein found abundantly in astrocytes.  This hGFAP-Cre transgenic line consists of a 
2.2-kilobase fragment derived from the 5’ promoter region of the gene.  This region was 
characterized previously and shown to be required for proper GFAP activity(103,104).  
hGFAP-Cre mice were shown to have Cre-recombinase expressed specifically in the 
brain though there was a small population of ductal cells in the liver that were 
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consistently positive(104).  Further investigation showed that positive cells included 
granule cells of the cerebellum, olfactory bulb, and dentate gyrus, hippocampal 
pyramidal cells, gray matter of the cerebral cortex, including virtually all neuronal cells, 
and ependymal cells lining the ventricular system.  Negative cell populations included 
Purkinje cells of the cerebellum, olfactory mitral cells, and spinal motoneurons, as well 
as choroid plexus.  Expression was first visualized beginning embryonic day 13.5 (E13.5) 
in the dorsal and medial aspects of the telencephalon.  By birth, the reporter was 
detected throughout the cortex and cerebellum.   
When crossed to our conditional knock-in animals, the use of the hGFAP-Cre 
strain of mouse would promote expression of mutant IDH1 in a very broad population 
of cells of the CNS, initially being expressed in multipotential NSCs that give rise to 
most cells of the brain.  This allowed us to ask what are the effects mutant IDH1 has on 
the CNS and what can we extrapolate from this system to learn about its function in 
tumorigenesis? 
hGFAP-Cre animals were crossed with our conditional knock-in IDH1-R132H 
animals.  Pups were genotyped as described in Appendix D and Materials and 
Methods.  As 2-HG is the metabolic product of mutant IDH1, we sought to detect 2-HG 
production in the brains of our mutant animals.  In collaboration with the 
Pharmacokinetics/Pharmacodynamics Core Facility at Duke University, and utilizing 
LC-MS-MS, we detected 2-HG in the brains of E15.5 animals (Materials and Methods).  
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Comparing levels of 2-HG among animals, those animals that were hGFAP-Cre; IDH1-
R132H (mutant animals) displayed a level of 2-HG 200-fold higher than in those animals 
that were hGFAP-Cre alone (12.23μg 2-HG/mg protein versus 0.054μg 2-HG/mg protein, 
respectively) (Figure 10).  This falls within range of what is observed in IDH1 mutant 
tumors compared to wildtype tumors which is 54.4μg 2-HG/mg protein versus 0.1μg 2-
HG/mg protein.  This suggests that the system is both genetically faithful and 
biologically relevant as it produces 2-HG at levels comparable to those detected in 
human samples(63). 
 
 
Figure 10:  2-HG in E15.5 brain homogenate. 
Brains were harvested from wildtype (hGFAP-Cre) and mutant (hGFAP-Cre; 
IDH1-R132H) E15.5 animals.  2-HG was detected at a level 200-fold higher in mutant 
brains compared to wildtype (unpaired, 2-tailed t-test: P-value=0.01990).  2-HG was 
detected via LC-MS-MS. 
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4.1  Broad expression of mutant IDH1 through the CNS induces 
hydrocephalus 
Initial experiments sought to determine the effects of mutant IDH1 on cells of the 
CNS.  To this end, we crossed our animals to the hGFAP-Cre strain of mouse that would 
induce expression in a tissue-specific manner, specifically in multipotential NSCs 
beginning at E13.5.  This leads to very broad expression throughout the cortex and 
cerebellum.  Animals that were generated included hGFAP-Cre animals as controls and 
hGFAP-Cre; IDH1-R132H animals as the experimental cohort.  Animals were monitored 
daily for any signs of neurological impairment that could be a result of tumor burden. 
Daily checks included observing animals for head doming, head tilts, ataxia, loss of grip 
capability, weight loss, dehydration, and any signs of pain including hunched posture or 
squinted eyes.  At the earliest signs of impairment or at 1-year of age, animals would be 
sacrificed and their tissues harvested for analysis (Materials and Methods).   
Physical differences among hGFAP-Cre animals and hGFAP-Cre; IDH1-R132H 
animals became apparent shortly after weaning age (after P21).  Physical differences 
included gradual enlargement of the head or head doming, squinted eyes, hunched 
posture, and gradual immobilization (Figure 11A,B).  This phenotype was present in 
80% of those animals that had mutant IDH1 expressed under control of hGFAP.  Control 
animals were non-phenotypic. 
Median survival for those 80% of animals was approximately 25.5 days, with 
some living as long as 50 days, at which point they had to be sacrificed (Figure 12). 
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Animals were sacrificed via lethal dose of urethane followed by intracardiac perfusion 
with PBS and 10% Neutral Buffered Formalin (Materials and Methods X).  Upon 
harvesting the brain, discoloration of tissue underlying the skull was observed.  
Dissection further showed large fluid filled cavities within an abnormal brain (Figure 
11C,D).  Formalin-fixed paraffin embedded blocks of tissue were sectioned and 
hematoxylin and eosin (H&E) stained (Materials and Methods).  Histological analysis 
showed that the large fluid filled cavities observed grossly were representative of a 
severe enlargement of the lateral ventricles (Figure 11E,F).  These features are 
characteristic of hydrocephalus and its induction is likely due to the broad expression of 
mutant IDH1 in the brain. 
 
Figure 11:  Broad expression of mutant IDH1 induces hydrocephalus. 
By weaning age, animals expressing mutant IDH1 presented with head-
doming, hunched posture, and squinted eyes (A and B).  Upon dissection, mutant 
brains displayed large fluid-filled cavities (C and D).  Histological analysis shows 
that these cavities were representative of a severe enlargement of the lateral ventricles 
indicating development of hydrocephalus (E and F).  Representative images shown 
above obtained from P38 animals. 
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Figure 12:  Survival of hGFAP-Cre; IDH1-R132H animals. 
Kaplan-Meier survival curve of animals expressing mutant IDH1 broadly 
throughout the brain.  Mutants display a significantly reduced survival (median 
survival 25.5 days compared to a normal-length survival for hGFAP-Cre wildtype 
counterparts).  Log-rank (Mantel-Cox) test shows significance with P<0.0001. 
 
According to the National Hydrocephalus Foundation, it is estimated that 
approximately 1 in 500 births results in hydrocephalus with another 6,000 more children 
developing it within the first 2 years of life.  Hydrocephalus is a condition in which 
excessive accumulation of cerebrospinal fluid (CSF) in the brain results in a widening of 
the ventricular spaces.  This widening creates a build up of pressure leading to harmful 
effects on the brain that, without treatment, will cause brain injury or even death.  The 
accumulation of CSF can result from an overproduction of CSF by the choroid plexus or 
it could be due to a failure to drain CSF at the subarachnoid space(105,106).  
Additionally, because there is an orchestrated flow of CSF throughout the brain, a 
blockage of flow through the narrow Sylvian aqueduct that lies between the third and 
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fourth ventricles could also cause hydrocephalus and is in fact one of the primary causes 
of it(106).  To this end, to determine whether development of hydrocephalus in mutant 
animals was due to an obstruction or blockage to any of these areas, coronal sections 
throughout the brain were made for histological analysis.  Though unable to identify the 
etiology of hydrocephalus in these animals, we did observe some instances of 
aqueductal stenosis and an overall loss of cellularity in mutant brains, which may be due 
to elevated levels of 2-HG.  We are currently working alongside a neurosurgeon at Duke 
University to better understand the basis for the development of hydrocephalus in these 
animals. 
4.2  Effects of mutant IDH1 on neural development 
Broad expression of mutant IDH1 throughout the brain led to a severe 
phenotype of hydrocephalus and deleterious effects to the brain.  The early onset of this 
dramatic phenotype required sacrificing the animals by P40, hindering the investigation 
of the prolonged effects of 2-HG on the brain and making it an unlikely model for 
studying 2-HG’s role in tumor induction.  Subsequent studies analyzed brains at an 
earlier timepoint, prior to the deleterious effects on the brain attributed to 
hydrocephalus.  Here, we asked what are the earliest effects mutant IDH1 is having on 
the brain, specifically on the neural stem cell population, a suspected cell of origin for 
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4.2.1  Mutant IDH1 induces foci of hemorrhagic lesions throughout 
cortex of developing brain 
The destruction attributed to hydrocephalus on hGFAP-Cre; IDH1-R132H brains 
impeded downstream analysis.  To assess the earliest effects of mutant IDH1 on the 
mouse brain and to do so on an intact brain without destructed tissue, we harvested 
samples from P3 animals.  Harvested tissues derived from hGFAP-Cre; IDH1-R132H 
animals were visibly different from their hGFAP-Cre control counterparts.  Dispersed 
throughout the cortex of the mutant animals were foci of hemorrhagic lesions (Figure 
13A and B).  These lesions were found in approximately 80% of those animals of the 
genotype hGFAP-Cre; IDH1-R132H.  No foci were observed in the hGFAP-Cre control 
animals.  H&E staining showed red blood cell extravasation in the mutant brains, 
however in the control brains, red blood cells were observed contained within vessels or 
capillaries (Figure 13C and D).  Due to this phenotype, we next sought to determine 
what the effects were on the endothelial cells and whether there was any defect that 
could be causing the extravasation.  IHC using the CD31 antibody was performed to 
detect the endothelial cells and observe any perturbations to their histology (Figure 13E 
and F).  We observed vessels to be thicker and stained more intensely with CD31 in 
mutant brains, suggesting that these tissues may be undergoing active 
angiogenesis(107).  
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Figure 13:  Mutant IDH1 induces hemorrhagic lesions. 
Broad expression of mutant IDH1 throughout the brain induces foci of 
hemorrhagic lesions as can be seen in mutant brains compared to wildtype brains (A 
and B (red arrows)).  H&E staining shows red blood cells within endothelial cells (red 
arrow) in wildtype brains (C), however, in mutant brains (D), there is mass red blood 
cell extravasation indicative of leaky vasculature.  Tissues were stained with CD31, a 
marker for vasculature.  In wildtype tissue (E) vasculature (black arrow) appears 
normal with red blood cells within the vessels (red arrow).  Mutant tissue (F) shows 
red blood cell extravasation (red arrows) and the vessels are staining deeper, though 
seem mostly normal.  Data collected from P3 animals. 
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Since generating our genetic mouse model, another mutant IDH1 mouse model 
has been described in the literature.  Sasaki et al., generated a mouse that expressed 
mutant IDH1 under control of Nestin-Cre.  In this case, Cre-recombinase is expressed as 
early as E10.5 and by E12.5, nearly all cells of the CNS express it.  These animals 
displayed perinatal lethality coupled with massive hemorrhage throughout the cerebral 
hemispheres and cerebellum as well as increased numbers of apoptotic cells(108).  This 
phenotype was observed as early as E15.5.  This group also utilized a GFAP-Cre strain of 
mouse, one that was generated independently using a different promoter region than 
the one our studies relied on.  Here, they observed the presence of hemorrhage, though 
this phenotype was variable among littermates.  As mentioned previously (Section 
2.3.2.3), the data describing mutant IDH1’s effects on HIF1α signaling is contradictory, 
with one group describing 2-HG blocking prolyl hydroxylation, allowing for HIF1α 
stabilization, whereas another group shows 2-HG activates prolyl hydroxylases, 
promoting the degradation of HIF1α(58,69).  Sasaki et al., attempted to resolve this issue 
and assess the in vivo effects of mutant IDH1 on HIF1α signaling and found it was 
stabilized, corroborating the study of Xu et al.  This is a cogent argument considering 
HIF1α’s involvement in neo-angiogenesis and induction of downstream targets 
including VEGF.  Interestingly for our studies, this may also explain the vascular 
leakiness observed in hGFAP-Cre; IDH1-R132H brains as increases in HIF1α and 
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subsequently, VEGF have been shown to induce gaps between adjacent endothelial cells 
lining microvessels promoting vascular leakiness(109).  
4.2.2  Mutant IDH1 perturbs the neural stem cell niche of developing 
animals 
hGFAP-Cre; IDH1-R132H animals became symptomatic by weaning age and had 
to be sacrificed by P40 (Figure 12).  Though this early termination prohibits the analysis 
of prolonged exposure of 2-HG on the brain, it does permit the study of the earliest 
effects of 2-HG on the brain, specifically on the NSC population of the developing 
organism.  By analyzing P3 brains, we assessed the effects mutant IDH1 is having on the 
NSC population of the brain and determined whether there are any defects to 
differentiation.  To date, the majority of studies dealing with mutant IDH1 and mutant 
IDH2 have been in the context of the hematopoietic system, adipocytes, or hepatocytes 
and all have shown that mutant IDH1 or mutant IDH2 confers a block to the normal 
differentiation patterns, leading to an accumulation of progenitor cells(56,70,78,79).  
Despite IDH1 being mutated at such a high frequency in CNS tumors, it is surprising 
that there is a deficit of data surrounding mutant IDH1’s effects on cells of the CNS in an 
in vivo context.  We characterized mutant IDH1’s effects on cells of the SVZ, the niche 
which houses the NSCs that give rise to the cells of the brain.  Being the SVZ is a 
germinal zone, we first assessed levels of proliferative cells in this region as those 
stained positively for the proliferative marker, Ki67 (Figure 14).  As expected, in hGFAP-
Cre animals, there was robust proliferation in the SVZ of the lateral ventricle.  The SVZ 
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in the same plane in hGFAP-Cre; IDH1-R132H animals displayed a reduction in the 
positively stained Ki67 cells, suggesting the proliferative capacity of these cells in 
blunted in mutant brains (Figure 15A).  
 
 
Figure 14:  Mutant IDH1 confers reduced proliferative potential of the SVZ as 
well as perturbed NSC niche. 
P3 brains from wildtype (A) and mutant (B) animals were stained with a 
marker for proliferation (Ki67) shown in green.  Mutant animals displayed a reduced 
proliferative potential of the SVZ.  Additionally, the NSC niche and the NSC 
population of the SVZ appeared perturbed in mutant brains as shown through 
staining with the NSC marker (Sox2), shown in red.  
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Figure 15:  Effects of mutant IDH1 on the SVZ. 
Quantification of Ki67 positive cells of the SVZ showed the presence of 
proliferative cells in the SVZ as expected in both hGFAP-Cre and hGFAP-Cre; IDH1-
R132H cohorts, however in mutant brains, proliferative capacity was significantly 
blunted (A).  Interestingly, the NSC population, as represented through Sox2 staining, 
shows an increase in the percentage of Sox2 positive cells in the SVZ in hGFAP-Cre; 
IDH1-R132H animals (B).  Two hGFAP-Cre and two hGFAP-Cre; IDH1-R132H 
samples were used for this quantification.  Two planes per sample were analyzed, all 
in the region of the apex of the lateral ventricle. 
 
As explained, the NSC niche consists of the SVZ of the lateral ventricle of the 
brain.  A variety of cell types are encompassed in this specialized niche and their proper 
regionalization and interaction with one another are imperative for their proper function 
and differentiation patterns.  The SVZ niche is composed of B1-cells, considered to be 
the NSCs and are surrounded by multi-ciliated ependymal cells.  The B1-cells give rise 
to C-cells, also known as transit amplifying cells that divide and generate neuroblasts, or 
A-cells.  Those cells born in this region migrate through an extensive network to reach 
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the rostral migratory stream where they will further migrate to populate the olfactory 
bulb.  Here, the cells will complete their differentiation into interneurons(110).  B1-cells, 
those considered to be the NSCs, make contact with the lateral ventricle with a thin 
apical process, while also making contact with blood vessels with a long basal process.  
For this reason, they are divided into three different domains, with each domain 
interacting with critical components for signaling.  For example, one domain (Domain I) 
of the B1-cell is in direct contact with the CSF, and thus receives soluble factors, while 
another domain, (Domain II) is in close contact with C-cells, permitting direct interaction 
with progeny.  Finally, Domain III comprises a basal process making contact with blood 
vessels allowing for reception of paracrine and endocrine signals(111).  The human brain 
is similarly structured as the described rodent brain, though it displays a more layered 
structure with Layer I consisting of an ependymal monolayer that has astrocytic 
processes intervening.  Layer II is a gap region that is hypocellular and contains basal 
processes of the ependymal cells.  This may function as a corridor for migrating cells.  
Layer III is composed of a dense ribbon of cell bodies and underlying this is the striatal 
brain parenchyma, Layer IV.  Proliferative cells were mostly found within layers II and 
III(112). 
As one of the suspected cells of origin for glioma are the NSCs, we sought to 
assess the effects mutant IDH1 was having on this population of cells.  We stained with 
the NSC marker, Sox2, and characterized the effects on the SVZ.  We observed that in 
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the hGFAP-Cre animals, the SVZ was very organized with a particular architectural 
layering consistent among wildtype animals (Figure 14).  The Sox2 population of cells 
lined this area and those cells that were staining positively for this NSC marker were 
restricted to this region.  hGFAP-Cre; IDH1-R132H animals displayed a perturbed NSC 
niche with Sox2 positive cells dispersed throughout the SVZ region as opposed to 
strictly within the region surrounding the ventricular walls.  Cells were not structured in 
the same fashion as in control animals as is indicated through the elevated ratio of Sox2 
positive cells emanating outward from the SVZ in mutant brains compared to wildtype 
brains (Figure 16).  This disorganization to the niche was consistent among those 
animals expressing mutant IDH1 in their brain and was not observed in control animals.  
Interestingly, when the number of NSCs of the SVZ were calculated and normalized to 
the overall number of cells in the region, there was a statistically significant increase in 
the number of Sox2 positively stained cells in mutant brains, suggesting that mutant 
IDH1 may be leading to an accumulation of NSCs in the SVZ and these cells may have 
an enhanced migratory ability.  Interestingly, a subsequent increase in proliferation has 
not been observed (Figure 15).  Though the observation of mutant IDH1 yielding an 
accumulation of progenitor cells has been observed before in other systems including 
the hematopoietic system, adipocyte lineage, and hepatocyte lineage, this is the first 
known example describing a similar effect of mutant IDH1 on cells of the CNS in an in 
vivo context.  It can be inferred that with the myriad of signaling pathways present 
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within the NSC niche, including SHH, Wnt, Notch, BMPs, and ephrin signaling, and 
many of those pathways relying on a structured cellular context, it is presumed that the 
perturbed architecture of this region will in fact disrupt proper neural differentiation 
patterns and migration of cells resulting from the NSC population. 
 
 
Figure 16:  Mutant brains display a dispersed Sox2 population of cells. 
Brains of hGFAP-Cre and hGFAP-Cre; IDH1-R132H were stained with Sox2, a 
marker for NSCs.  Two separate planes among 2 wildtype and 2 mutant brains were 
analyzed.  For each, a 200 X 200 pixel region placed with its left side along the 
ventricular wall.  This is the left-most blue and green column shown above.  Total 
nuclei and Sox2 positive cells were counted.  The area immediately adjacent to this 
first region was then counted, followed by the region immediately adjacent to this 
one for a total of three regions to properly show the proportion of Sox2 positive cells 
throughout this region of the brain. 
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4.3  Discussion 
We sought to determine the effects of mutant IDH1 on the mouse brain and we 
initiated our studies by expressing mutant IDH1 very broadly throughout the brain 
through the use of the hGFAP-Cre model.  With this system, we were able to detect 2-
HG at a level 200-fold higher than in control animals, suggesting the system was 
working and it was producing 2-HG at a level comparable to what is observed in human 
glioma samples with IDH1 mutations.  80% of these animals became symptomatic very 
early in development leading to a median survival of approximately 25.5 days.  Upon 
harvesting the tissues, we determined that broad expression of mutant IDH1 in the brain 
induces hydrocephalus, a dramatic phenotype that made investigation of the long-term 
effects of 2-HG on the brain impossible.  However, it is interesting to note that it has 
been described in a case study that those patients with 2-hydroxyglutaric aciduria do 
present with mild ventriculomegaly.  Many believe that ventriculomegaly is early on the 
spectrum for development of hydrocephalus and this may be the first animal model that 
shows a link between 2-HG production and enlargement of the lateral ventricles.  
Though unlikely, it would also be interesting to know whether 2-HG can be detected in 
patients that do develop hydrocephalus for reasons other than 2-hydroxyglutaric 
aciduria.   
As mentioned, though our system did not permit the study of the long-term 
effects of 2-HG on cells of the brain, it does permit the study of the earliest effects of 
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mutant IDH1 on a cell type considered to be the cell of origin for glioma, the NSCs.  
Observation of younger animals showed areas of hemorrhagic foci and leaky 
vasculature within the brain that may be due to increased levels of HIF1α as a result of 
elevated levels of 2-HG.   
As mentioned, 20% of hGFAP-Cre; IDH1-R132H animals were asymptomatic 
and survived to the 1-year experimental endpoint.  With no signs of any neurological 
impairment or hydrocephalus, it is possible that this is due to variable Cre-expression.  
This phenomenon has recently been characterized in a variety of Cre-driver strains and 
has been shown that even among littermates, there could be significant differences in the 
reporter readout(113).  As more samples become available, it would be interesting to 
analyze the precise level of 2-HG being produced and determine whether there are any 
subtle lesions that may not have been grossly apparent.  If 2-HG is being produced at 
detectable levels, it would be very interesting to learn what prolonged exposure would 
induce in these animals and whether there are any neoplastic or preneoplastic lesions 
present within the brain.  Additionally, it would be interesting to learn whether mutant 
IDH1 alone or in cooperation with other mutations, such as deletions in TP53, would be 
capable of inducing tumorigenesis.  Perhaps a lower level of 2-HG production over 
prolonged periods of time is required to promote tumorigenesis; a level that is 
surmounted in the 80% of symptomatic animals. 
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Taking into account the scope of phenotypic variation among different models, it 
appears that the timing of the induction of mutant IDH1 is imperative.  The published 
Nestin-Cre system has mutant IDH1 being induced at E10.5.  In our GFAP-Cre system, 
Cre-recombinase is induced at E12.5.  In both cases, signs of hemorrhage were apparent, 
however in the former case, animals displayed perinatal lethality.  In the latter case, 
animals were able to survive to post-weaning age, however they succumbed to the 
devastating deleterious effects of hydrocephalus.  This suggests that by restricting 
expression to a more specific cell type, and induction of recombination at different times 
may circumvent issues of lethality.  To this end, achieving spatio-temporal control over 
mutant IDH1 expression, as will be described in the following chapter utilizing our 
Nestin-CreERT2 system, may permit a model with prolonged exposure to 2-HG and thus 
generate a more amenable system to tumor modeling. 
Despite the high frequency of IDH1 mutations in CNS tumors, there has been a 
lack of data describing mutant IDH1’s effects on cells of the CNS, particularly in an in 
vivo context.  Most studies have relied on immortalized astrocytes or established glioma 
cell lines such as U87(58,59).  However, our studies are among the first to characterize 
the effects of mutant IDH1 on the mouse brain in a genetic system.  Our findings 
included a reduction in the proliferative cells present in the SVZ of the lateral ventricles 
of mutant brains.  Though the reduction in proliferative cells was surprising, it is 
consistent with some published data suggesting that mutant IDH1 decreases rates of 
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proliferation(59).  Together, these data offer one reason why primary cell lines that 
contain IDH1 mutations are so difficult to establish in culture and xenografts(61).  In this 
same region, an increase in the Sox2 positive population was observed and these cells 
tended to migrate outwards from the SVZ to an extent that was not observed in 
wildtype brains.  We can infer that considering this specialized microenvironment is 
critical for the regulation of proliferation and progenitor cell differentiation, it is likely 
that the observed disorganization perturbs the normal differentiation patterns of the 
resident NSCs.  The signaling pathways of this region have been well characterized and 
include SHH, Wnt, Notch, BMPs, and ephrin signaling, therefore any disruption to the 
highly ordered structure that is normal for this area is likely to skew proper signaling 
and cues for differentiation which may have implications in tumor initiation and 
development(10). 
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5.  Introduction:  Achieving spatio-temporal control over 
expression of mutant IDH1 in the mouse brain  
The previous model generated had mutant IDH1 expressed very broadly 
throughout the cortex and cerebellum of the brain.  Though the precise etiology of the 
hydrocephalus that developed in these animals is as of yet, unknown, there is the 
possibility mutant IDH1 was expressed in critical cells too early in development leading 
to a developmental defect and masking any further effects that may be more relevant to 
tumorigenesis.  In addition to the fact that mutant IDH1 induces hydrocephalus when 
broadly expressed throughout the brain, we also learned that early induction of mutant 
IDH1 can perturb the developing brain in several other ways including: 1-mutant IDH1 
imparts a negative effect on the proliferative potential on cells of the SVZ; 2-mutant 
IDH1 promotes an accumulation of Sox2 positive NSCs in the SVZ region that tend to 
migrate outwards from their normal location surrounding the ventricular wall; 3-mutant 
IDH1 causes a structural disorganization to the SVZ; and 4-mutant IDH1 perturbs the 
architecture of the NSC niche, likely altering the many signaling pathways within it and 
subsequently effecting the normal neural differentiation patterns that are crucial to 
developing an intact brain.  These effects of mutant IDH1 are encouraging as it suggests 
that by restricting expression to a more specific cell type and at a more appropriate time, 
that we would circumvent the lethality attributed to hydrocephalus.  This would allow 
for the affected cells to persist longer, permitting a more thorough understanding of the 
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effects mutant IDH1 and 2-HG are having on these cells over a prolonged period of time.  
In order to restrict expression of mutant IDH1 to a more specific cell type, we crossed 
our mutant IDH1 conditional knock-in animals to a Nestin-CreERT2 strain of mouse.  In 
contrast to the hGFAP-Cre strain of mouse used in our previous experiments, the 
Nestin-CreERT2 strain of mouse has Cre-recombinase inducibly activated under control 
of a tissue-specific promoter.  This ligand-dependent Cre-recombinase is activated 
through administration of tamoxifen to the animal, at which point the Cre-recombinase 
is translocated to the nucleus where it imparts its excision capabilities.  In the hGFAP-
Cre system, Cre-recombinase was expressed beginning at E12.5 and continues to be 
expressed whenever and wherever GFAP is active.  Though Nestin begins to be 
expressed at E9.5, the Cre-recombinase will only become activated once tamoxifen is 
administered and only in those cells expressing Nestin, thereby conferring spatio-
temporal control over induction of mutant IDH1.  By restricting the expression of 
mutant IDH1 to later stages where fewer cells would be targeted, allows us to 
circumvent the hydrocephalic phenotype and assess the effects of mutant IDH1 and 2-
HG on the brain over prolonged periods of time.  In fact, one of the many advantages of 
using the CreERT2 system is for this very reason, to bypass the untimely lethality or other 
undesirable effects that impede the study of the true function of a genetic alteration. 
The Nestin-CreERT2 mouse was generated using a 1.8 kilobase fragment of rat 
genomic DNA containing the second intron of Nestin(114).  Nestin is an intermediate 
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filament protein that is expressed in both neuroepithelial stem cells as well as muscle 
precursor cells.  Prior studies have characterized enhancer regions of this gene that 
delineates its expression patterns; it was shown that the second intron is responsible for 
restricting Nestin expression to the CNS and thus the reason this region was used in the 
making of this transgenic animal(115).  The characterization of this promoter region 
shows Nestin being expressed beginning at E9.5 and expressed in the ventricular and 
nonventricular proliferative zones of the mammalian CNS.  However, it was not 
expressed in postmitotic neurons and glia, nor in the myotome, suggesting this enhancer 
region confers specificity to the NSC population.  By inducing mutant IDH1 expression 
at specific times throughout embryonic or adult life, we would circumvent the 
hydrocephalic phenotype and acquire the ability to assess mutant IDH1’s effects on the 
brain, specifically on the NSC population of the brain, a leading candidate as the cell of 
origin for gliomas. 
5.1  Induction of mutant IDH1 in a restricted cell population in 
the CNS 
One of the huge advantages of generating genetic mouse models is the ability to 
control the system.  Through the variety of Cre-drivers that are available, one can 
achieve tissue-specific expression or knock-out of your gene of interest.  Additionally, 
utilizing CreERT2 drivers, you can control the timing of that tissue-specific expression or 
knock-out through administration of tamoxifen.  Though this level of control is a huge 
asset and makes for a scientifically precise model, it also requires a great deal of thought 
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as there are often no single answers to the many questions that arise.  For example, one 
must decide which Cre or CreERT2 driver to utilize.  Though this is in theory straight 
forward, knowing the precise cell types in which Cre-recombinase is being expressed is 
not a trivial undertaking and is dependent on how well that tissue is characterized as 
well as on the markers that are available for the tissue.  The extent of cellular 
heterogeneity within that tissue is also important as it may not be the case that every cell 
type within that tissue will express Cre-recombinase.  To know which ones specifically 
are expressing will help draw conclusions when phenotypes present themselves.  The 
CreERT2 system presents another set of questions including when is the proper time to 
treat with tamoxifen and activate Cre-recombinase.  This requires accurate knowledge of 
the driver being used considering Cre-recombinase will not be activated unless the 
promoter is active.  A knowledge of the gene activity itself is not always enough for this 
as many times the promoters are composed of different enhancer regions and may 
display differential expression from what the expected gene expression pattern is.  
Lastly, the tamoxifen treatments required to achieve an extent of recombination desired 
must be assessed.  A single dose of tamoxifen may or may not be sufficient for particular 
studies.  In summation, genetic models and inducible activation or knock-out of genes 
presents a tremendous amount of wealth and value to the studies, however they require 
a tremendous amount of responsible and well-informed decisions to achieve that wealth 
and value. 
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Our studies sought to induce mutant IDH1 in the SVZ of the lateral ventricle of 
the mouse, with the goal of targeting the NSC population.  To initiate the studies, we 
crossed in a conditional reporter mouse that had a 1.6-kilobase fragment encoding the 
tdTomato protein that lied downstream of a floxed stop cassette (referred to as 
LSLtdTomato)(116).  Upon expression of Cre-recombinase, the stop cassette would be 
excised inducing expression of tdTomato, a Red Fluorescent Protein (RFP) variant.   
As our goal was to express mutant IDH1 in the NSC population, we additionally 
crossed in the Nestin-CreERT2 strain, described above, that has Cre-recombinase 
inducibly activated in the SVZ of embryonic and adult animals.  Experimentally, our 
plan once animals were generated was to have two groups, each one treated with 
tamoxifen at a different time and thus inducing recombination in a restricted fashion 
(Figure 17).  As our goal was to generate a faithful model of mutant IDH1-mediated 
gliomagenesis, and knowing that these tumors present in humans in early adulthood, 
we chose to treat our animals with tamoxifen at P28, a timepoint that represents early 
adulthood in mouse.  However, in the characterization of this strain of mouse, we knew 
that Nestin expression significantly decreases postnatally, and that by treating at this 
timepoint we may not be inducing recombination in enough NSCs to promote a 
tumorigenic phenotype.  To this end, another group of animals were treated at E18.5 via 
oral gavage to the pregnant dams, a timepoint that would be targeting more cells than at 
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P28, but not as many cells as were induced in the hGFAP-Cre system described 
previously (Figure 17). 
 
Figure 17:  Experimental plan for Nestin-CreERT2 animals. 
Mutant animals were crossed with Nestin-CreERT2.  Two groups were treated, 
one at E18.5 and another group at P28.  Matings were timed based on the presence of a 
vaginal plug which designated E0.5dpc.  At either 18.5dpc for the E18.5 timepoint or at 
P28, pregnant dams or experimental animals were treated with tamoxifen, 
respectively.  At 1-year or at the earliest sign of neurological impairment, animals 
were sacrificed and tissues harvested for analysis. 
 
As validation that our system was working as expected, pregnant females 
yielding progeny of the genotype Nestin-CreERT2; LSLtdTomato were treated with 
tamoxifen (150μl of 20mg/ml tamoxifen made up in sterile corn oil) and treated at 
18.5dpc to test Cre-recombinase induction and recombination efficiency for the E18.5 
timepoint (Materials and Methods).  Pups were sacrificed at P3 to assess recombination 
throughout the brain.  Tissues were processed as explained in Materials and Methods 
and stained with an antibody specific for RFP.  As expected, those animals treated with 
 92 
tamoxifen displayed robust expression of RFP in the SVZ of the lateral ventricle (Figure 
18).  It should be noted that untreated animals displayed minor random recombination 
events throughout the brain however, these were sporadic events and highly unlikely to 
impact experimental results (Figure 18).  This could be due to leaky Cre-recombinase, a 
phenomenon that has been documented and is common among many characterized 
transgenics(117,118).   
 
 
Figure 18:  Treatment with tamoxifen at E18.5 induces recombination in the 
SVZ. 
Timed matings generating Nestin-CreERT2; LSLtdTomato progeny were 
established.  At 18.5dpc, pregnant dams were either treated with tamoxifen via oral 
gavage or not treated.  At P3, pups were sacrificed and tissues stained for RFP.  (A) 
Untreated animals show minimal recombination and RFP induction in the SVZ 
suggesting a minimal level of leaky Cre-recombinase.  (B) Treated animals show 
robust expression of RFP in the SVZ as expected, suggesting treatment with 
tamoxifen at E18.5 induces recombination in our cell of interest at an appropriate 
level. 
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5.2  Mutant IDH1 and TP53 deletion promote brain tumorigenesis 
in genetic mouse model 
To achieve expression of mutant IDH1 in a cell type suspected of being the cell of 
origin for gliomas, while circumventing the hydrocephalic and thus, lethal phenotype 
that was observed when it was broadly expressed, we crossed our mutant IDH1 
conditional knock-in animals to Nestin-CreERT2.  To fully recapitulate the mutation 
spectrum observed in human glioma we also incorporated conditional deletion of those 
other most commonly mutated genes including ATRX and TP53, as described 
previously.  As explained, we would have two cohorts of animals with one group being 
treated at E18.5, and the other group being treated at P28.  After several months, it 
became apparent that the P28 treated animals were asymptomatic under the specified 
conditions, that being a single dose of tamoxifen at P28.  Therefore, the remainder of the 
studies focused on the E18.5 treated animals. 
Following administration of tamoxifen to pregnant dams, animals were 
monitored daily for any signs of neurological impairment that could be a result of tumor 
burden. Daily checks included observing animals for head doming, head tilts, ataxia, 
loss of grip capability, weight loss, dehydration, and any signs of pain including 
hunched posture or squinted eyes.  At the earliest signs of impairment or at 1-year of 
age, animals would be sacrificed and their tissues harvested for analysis (Materials and 
Methods).   
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These experiments were established to assess whether mutant IDH1 can induce 
brain tumorigenesis alone or in combination with other genetic aberrations.  Once 
tumors formed, they would be characterized and compared to determine the role 
mutant IDH1 plays in tumorigenesis.  Additionally, the mutations contribution to 
overall survival as a result of tumor aggressiveness would be assessed.  The genotypes 
that were generated for this study include mutant IDH1 alone, TP53 deleted alone, and 
mutant IDH1 with TP53 deleted.  Additionally, a cohort of animals that contained 
deletion of ATRX was incorporated.  
At the culmination of this experiment, several findings were made.  For one, 
when IDH1 is mutated on its own, survival was indistinguishable from animals with no 
mutations (Figure 19).  This corroborates previous studies and implies that mutant IDH1 
requires additional mutations in order to promote a tumorigenic phenotype.  To this 
end, tumors did form in those animals harboring mutant IDH1 and TP53 deletion.  
Additionally, tumors also developed in mice with TP53 deleted alone.  It should be 
noted that in both cohorts, tumors were only observed when both alleles of TP53 were 
deleted.  Having generated essentially two groups of tumors, those tumors with mutant 
IDH1 and deleted TP53, and those with only TP53 deleted alone, we next sought to 
assess the differences between these genotypically different tumors.   
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Figure 19:  Survival of Nestin-CreERT2 animals. 
Kaplan-Meier Survival Curve for animals treated at E18.5 to inducibly activate 
mutant IDH1, deletion TP53, or both.  Animals were aged for 1-year.  At the earliest 
sign of impairment or at 1-year, animals were sacrificed.  Animals with mutant IDH1 
activated alone exhibited no differences in survival compared to normal mice; 
suggesting cooperating mutations are required for tumorigenesis.  When TP53 is 
homozygously deleted, animals became symptomatic often displaying signs of brain 
tumor including head-doming and ataxia.  Nestin-CreERT2; IDH1-R132H; TP53fl/fl 
displayed a median survival of 357 days whereas Nestin-CreERT2; TP53fl/fl animals 
displayed a median survival of 334.5 days. 
 
To begin looking for distinguishing features between mutant IDH1; TP53 deleted 
tumors, and TP53 deleted tumors, we first sought to ensure that those tumors arising in 
animals containing the mutant IDH1 allele were in fact expressing the mutant IDH1 
protein.  To this end, we performed IHC using an antibody specific for mutant IDH1-
R132H which was tested on a Nestin-CreERT2  brain as well as a hGFAP-Cre; IDH1-
R132H brain for negative and positive control, respectively (Figure 20)(Materials and 
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Methods).  We then tested the reactivity of the antibody on tumors derived from mutant 
IDH1 and TP53 deleted tumors, and TP53 deleted tumors alone.  Only those tumors that 
developed in animals of the genotype Nestin-CreERT2; IDH1-R132H; P53fl/fl showed 
staining with the IDH1-R132H antibody.  Intense staining was observed only in the 
tumor area, but not in the surrounding brain parenchyma (Figure 21).  This was in 
contrast to those tumors that developed in animals of the genotype Nestin- CreERT2; 
P53fl/fl which showed a complete lack of staining (Figure 21).  This suggests that mutant 
IDH1 is being expressed in those mutant tumors and should, in theory, be conferring a 
difference when compared to the IDH1 wildtype cohort of tumors. 
It has been shown that gliomas with mutations in IDH1 develop preferentially in 
the frontal lobe, thus we sought to determine whether tumor localization would be able 
to distinguish these genotypically different tumors(83).  Based on location alone 
however, these tumors were unable to be distinguished as tumors from both genotypes 
presented throughout the cortex of the brain (Figure 22).  As the brains of mice are not 
identical to that of humans, coupled with the structure being smaller, the fact that the 
tumors did not localize exclusively in the frontal area of the mouse brain is not 
surprising. 
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Figure 20:  Optimization of the IDH1-R132H antibody. 
The antibody against IDH1-R132H was tested for its reactivity against samples 
expressing endogenous wildtype IDH1 (A and C) (Nestin-CreERT2 animals-negative 
control) or mutant IDH1 (B and D) (hGFAP-Cre; IDH1-R132H animals-positive 
control).  Positive staining is present only in those animals expressing mutant IDH1 
(B and D).  Staining with IgG2A isotype control shows no staining in either 
circumstance (E and F). 
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Figure 21:  Detection of IDH1-R132H in tumors containing the mutant IDH1 
allele. 
The mutant IDH1 antibody specific for IDH1-R132H was used to detect 
expression of the mutant allele.  TP53 deleted tumors (A) were compared with mutant 
IDH1; TP53 deleted tumors (B).  Only those tumors containing the IDH1-R132H allele 
were positively stained with the mutant IDH1 antibody. 
 
To better characterize the tumors that developed, they were stained with a 
variety of markers that neuropathologists use to aid in diagnosis.  Among our antibody 
cohort were markers for astrocytes (GFAP), oligodendrocytes (Olig2), NSCs (Nestin), 
neuronal cells (NeuN or NFP), neuroendocrine cells (Synaptophysin), endothelial cells 
(CD31), and proliferative cells (Ki67).  These markers give insight into the cell types that 
the tumor is composed of as well as their behavior.  For example, if the tumor displays 
strong staining with GFAP, and has a high percentage of Ki67 positive cells, it suggests 
that the tumor may be an astrocytoma.  These markers in combination with histology 
give a further understanding of the aggressiveness of these tumors.  A summary of the 
findings derived from histology and IHC as reported by our resident neuropathologist 
can be found in Table 2 and Figure 23.  We observed that the tumors were variable in  
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Figure 22:  Tumor localization. 
Mutant IDH1 tumors tend to present in the frontal lobe of human patients.  To 
determine whether our system recapitulated this, we compared the location of the 
tumors that developed among Nestin-CreERT2; IDH1-R132H; TP53fl/fl (top half) and 
Nestin-CreERT2; TP53fl/fl (bottom half).  Note sample C096 LtAgM shown in orange 
was the only low-grade glioma observed and of the genotype Nestin-CreERT2; IDH1-
R132H; TP53fl/fl; ATRXfl/fl. 
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their histological appearance and included diagnoses of low-grade GBM, high-grade 
GBM, and even an anaplastic embryonal tumor.  Interestingly, the only low-grade tumor 
observed was of the genotype Nestin-CreERT2; IDH1-R132H; P53fl/fl; ATRXfl/fl, the most 
common signature for the low-grade gliomas observed in human patients (Figure 24).  
Most other tumors were high-grade and included molecular features of GBMs including 
pseudopalisading necrosis and a diffuse and infiltrative nature observed through 
histology (Figure 24).  The majority of the tumors stained positively for GFAP, but this 
was determined to be reactive astrocytosis and spanned genotypes.  Additionally, giant 
cells were observed in several of those tumors that were IDH1 mutant (Figure 24).  Giant 
cells are found in human glioma samples and there has been some thought that they are 
associated with a better survival(119). 
Ki67, a marker for proliferative cells was also assessed.  This marker is 
commonly used to assess the aggressiveness of a tumor and the extent of actively 
dividing cells.  Interestingly, in our cohort, those tumors harboring the IDH1-R132H 
mutation and TP53 deletion tended to have a higher proliferation index compared to 
those tumors with TP53 deleted alone, with 68% compared to 38% of tumor cells 
staining positively for Ki67, respectively (Figure 25).  It is to be noted that because one of 
the IDH1-R132H expressing tumors was very different histologically, with a chondroid-
like appearance, as well as with regard to its proliferative index, this sample was 
removed from the comparison described above.  
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Lastly, we analyzed the overall survival of these animals and observed that 
mutant IDH1 confers a slight survival advantage of 357 days versus 334.5 days when 
comparing those animals of the genotype Nestin-CreERT2; IDH1-R132H; P53fl/fl with 
Nestin-CreERT2; P53fl/fl (Figure 19).  Though not statistically significant, the trend 
corroborates several previous studies, including several from our own laboratory, 
showing those brain tumor patients with mutations in IDH1 have a prolonged survival 
when compared to patients with wildtype IDH1 (20 months versus 65 months for 
patients with anaplastic astrocytoma (Grade III) for patients with IDH1 wildtype versus 
mutant tumors, respectively, and 15 months versus 31 months for patients with GBM 
(Grade IV) for patients with wildtype versus mutant tumors, respectively)(25,37). 
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 Table 2:  IHC Characterization of Select Tumors. 
Summary of findings and notes for several tumors (either Nestin-CreERT2; IDH1-R132H; P53fl/fl or Nestin-CreERT2; 
P53fl/fl) that were analyzed through IHC using markers used for neuropathological diagnosis. 
. 
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Figure 23:  Tumor characterization. 
To distinguish genotypically different tumors, IHC was performed with a variety of markers: Ki67 (proliferation), 
Nestin (NSCs), GFAP (astrocytes), Olig2 (oligodendrocytes), NFP (neurons), Synaptophysin (MBs), and CD31 
(vasculature).  Regions shown are either of tumor bulk or border region between tumor and normal tissue.  Sample 
names: N-Nestin-CreERT2; I-IDH1-R132H; P-P53fl/fl; A-ATRXfl/fl.
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Figure 24:  Histological features of brain tumors. 
Representative images of tumors that developed in Nestin-CreERT2; IDH1-
R132H; TP53fl/fl animals(A-C) as well as Nestin-CreERT2; TP53fl/fl(D-E).  Additionally, 
one low-grade tumor was observed in a Nestin-CreERT2; IDH1-R132H; TP53fl/fl; 
ATRXfl/fl animal(F).  (A’-F’) are 20x images of tumor region for respective samples.  (A) 
shows a tumor of chondroid-like histology.  Other tumors in this cohort were more 
typical with diffuse and infiltrative nature, mitotic figures, and giant cells (red 
arrows).  (D-E) show higher levels of mitotic activity and a less-differentiated 
population of tumor cells.  (F) shows a low-grade tumor with low levels of mitotic 
activity.  Diffuse disease that respects borders can be seen. 
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Figure 25:  Mutant IDH1 tumors display heightened proliferative capacity. 
Ki67 staining was compared among Nestin-CreERT2; P53fl/fl and Nestin-
CreERT2; IDH1-R132H; P53fl/fl tumors.  Tumors expressing mutant IDH1 and TP53 
deletion contained approximately 20% more proliferative cells than their TP53 deleted 
alone counterpart. 
 
5.3  Discussion 
When mutant IDH1 is broadly expressed throughout the brain, as was the case 
when we crossed our conditional knock-in animals to hGFAP-Cre, the animals 
developed hydrocephalus relatively early on.  This prohibited the investigation of 
determining mutant IDH1’s effects on the brain, specifically 2-HG’s effects on the brain 
for prolonged periods of time.  To circumvent this issue and to restrict expression to one 
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of the leading candidates for the cell of origin for glioma, the NSCs, we crossed our 
animals to Nestin-CreERT2 which has Cre-recombinase inducibly activated in the SVZ of 
embryonic and adult animals.  In doing so, we achieved spatio-temporal control over 
expression of mutant alleles.  In addition to the conditional knock-in of mutant IDH1 
that we generated, a conditional deletion of TP53, and a conditional deletion of ATRX 
were incorporated into the system.  In this way, we recapitulated the genetic signature 
of the astrocytic subset of gliomas and were able to induce these mutations in the NSC 
population of the organism.  Tumors developed in animals that harbored mutant IDH1 
with homozygous deletion of TP53 as well as in animals that had TP53 deleted by itself. 
Mutant IDH1 was detected via IHC using an IDH1-R132 specific antibody in those 
tumors that contained the mutant IDH1 allele.  This allows for us to assess the effects of 
mutant IDH1 in a genetically-based, tumor-specific context.  All tumors varied 
histologically as well as in diagnosis making it difficult to draw distinctions among these 
genotypically different tumors.  However, there were some features that presented only 
in mutant IDH1 tumors.  These features included the presence of giant cells, an 
increased percentage of proliferative tumor cells, as indicated through Ki67 staining, as 
well as a trend towards a better survival when compared to the wildtype IDH1 cohort.  
In summary, we found that mutant IDH1 on its own is incapable of driving 
tumorigenesis in this system and implies that though important for tumorigenesis, as is 
indicated by its high frequency of mutation in glioma, it is not sufficient to induce 
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tumors on its own.  We show that other mutations are needed in order to promote 
tumorigenesis, such as deletion of TP53, or other mutations in tumor suppressors or 
oncogenes that have gone uninvestigated in these sets of experiments.  Though tumors 
developed in our system, they did so at a low penetrance with approximately 15% of 
treated animals becoming symptomatic.  The latency was rather long for our system, 
with some animals showings signs of symptoms by day 179, and other animals showing 
no signs of symptoms or brain tumor until sacrifice and histological analysis of the brain 
at the 1-year timepoint.  We have recently begun to utilize the data from these studies to 
further investigate the role of mutant IDH1 and cooperating mutations in driving 
tumorigenesis by implementing an orthotopic intracranial injection model based on 
NSCs derived from our genetic system or from serial transplanted brain tumor cells 
generated from our current system.  This will be discussed in the following chapter 
discussing ongoing and future investigations stemming from these discoveries.  
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6.  Discussion of current research and future directions 
As has been discussed in previous chapters, we have utilized the power of 
Sanger sequencing and whole exome sequencing of both low- and high-grade gliomas to 
establish genetic signatures that could be used toward the stratification of human 
patients.  We described that astrocytomas tend to harbor mutations in IDH1 or IDH2, 
TP53, and ATRX, while oligodendrogliomas contain mutations in IDH1 or IDH2, and 
CIC or FUBP1 together with chromosomal loss of 1p/19q, all aberrations that can be 
relatively easily detected through PCR or hybridization reactions (Figure 4).  
Neuropathologists currently rely predominately on histological analysis of tumor tissue 
for patient diagnostics, however there is a great deal of inter-institutional variation and 
bias.  This discrepancy leads to the non-uniform treatment of patients, hindering both 
patient outcome and analysis of effectiveness of particular drugs on specific glioma 
subtypes.  Diagnosing glioma subtypes via molecular genetic signatures has the ability 
to complement histological analysis and offer a non-biased, invariable, and perhaps 
even binary means of diagnosis that can preclude the inter-institutional variability that 
plagues the field.  Recently, we have discovered an additional component to the genetic 
signatures that makes the stratification of glioma subtypes even easier and more 
straightforward.  That is, we identified the presence of promoter mutations in telomerase 
reverse transcriptase (TERT) in a large cohort of gliomas.  Specifically, we found TERT 
promoter mutations in the majority of primary GBMs, TERT promoter mutations and 
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IDH1 or IDH2 mutations in oligodendrogliomas, and mutations in IDH1 or IDH2 and 
ATRX but a lack of TERT promoter mutations in the astrocytic subset of gliomas 
including the secondary GBMs(37,120).  Note, this paper and the findings within are 
explained further in Appendix B.   
Utilizing the data obtained from our genetic studies, we sought to generate 
genetically faithful mouse models of glioma.  We generated an IDH1-R132H conditional 
knock-in mouse model and crossed these animals to two different strains of mouse that 
have Cre-recombinase driven by either the hGFAP promoter or the Nestin promoter.  
When broadly expressed throughout the brain, we determined that mutant IDH1 
induces a dramatic hydrocephalic phenotype.  We determined that mutant IDH1 
conferred a negative effect on the proliferation status of cells of the SVZ, as indicated 
through a reduction in the Ki67 staining in an otherwise robustly proliferative region of 
the brain.  In the other hand, we did observe an increased percentage of Sox2 positive 
cells, or NSCs in this region.  Upon characterizing this further, we observed that these 
Sox2 positive cells tended to be more dispersed, emanating from the normally tightly 
structured SVZ in comparison to the wildtype NSCs.  With the NSC population diffuse 
throughout this area and an overall disorganization to this region which otherwise 
displays a very architectured nature, it is likely that mutant IDH1 is affecting the normal 
signaling pathways that are active and imperative for the proper differentiation patterns 
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for achieving the cellular diversity required for proper neural development of these 
animals.   
To achieve a prolonged exposure of cells of the CNS to 2-HG such that the 
animals do not become symptomatic from hydrocephalus, we harnessed spatio-
temporal control over expression of mutant IDH1 thereby increasing the likelihood of 
mutant IDH1-mediated tumor development.  This was performed through inducible 
activation of mutant IDH1 via administration of tamoxifen in Nestin-CreERT2; IDH1-
R132H animals.  We also incorporated additional mutations to best recapitulate the 
mutation spectrum observed in human glioma samples, including conditional deletion 
of TP53 and conditional deletion of ATRX.  We did observe tumor development in 
animals with mutant IDH1 expressed and TP53 deleted, as well as in animals with TP53 
deleted alone.  Overall, tumors were variable in nature ranging from low-grade gliomas, 
high-grade gliomas, and primitive neuroectodermal tumors.  Most displayed an 
aggressive phenotype with a diffuse and infiltrative nature.  Mutant IDH1 was detected 
in those samples harboring the mutant IDH1 allele, and mutant IDH1 was not detected 
in those tumors with TP53 deleted alone suggesting there should be observable or 
molecular difference in those tumors expressing mutant IDH1 that should be exploited.  
Additionally, those tumors expressing mutant IDH1 tended to have higher levels of 
proliferative cells (66% compared to 38%).  Despite a higher level of proliferation in 
these mutant animals, they did trend toward a better survival (357 days versus 334.5 
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days) for mutant animals versus wildtype animals.  This corroborates human data in 
that patients presenting with mutations in IDH1 tend to have a better survival than their 
wildtype counterparts.   
Considering broad expression of mutant IDH1 lead to a dramatic hydrocephalic 
phenotype, and restricted expression of mutant IDH1 lead to development of tumors 
when co-mutated with TP53, but did so with a long latency and low penetrance, we are 
currently working towards improvement of the system.  To this end, we have generated 
an orthotopic intracranial injection model utilizing NSCs derived from our genetic 
model.  Here, we crossed in a conditional reporter mouse to our mutant IDH1 
conditional knock-in animals (conditional deletion of TP53 and conditional deletion of 
ATRX were also incorporated).  NSCs were isolated from E14.5 embryos and cultured in 
vitro (Materials and Methods).  After 1-day in culture, NSCs were infected with 
adenoviral Cre-recombinase.  By 24-hours post-infection, expression of tdTomato was 
detected through fluorescence microscopy.  Additionally, 2-HG was detected in only 
those NSCs harboring the mutant IDH1 allele following transformation with Cre-virus 
(Figure 26).  These NSCs were subsequently used for orthotopic intracranial injection 
into recipient mice.  As a pilot study, these cells were injected into NOD scid gamma 
animals (NSG), an immune-compromised strain of mouse that is commonly used for 
injections of cells that would otherwise promote an immune response(121).  Considering 
these cells are capable of indefinite in vitro culture, this opens up a new avenue for 
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incorporating other mutations and drivers to best determine the cooperating nature 
among mutations identified in human patients.   
 
 
Figure 26:  Derivation and induction of mutant alleles in NSCs. 
NSCs were harvested from E14.5 animals and cultured in vitro as neurospheres 
(A).  Cells were infected with adenoviral Cre-recombinase (B).  This induced 
expression of the tdTomato reporter in the infected cells, but not the non-infected or 
wildtype cells(C and D).  2-HG was detected in only those cells that were infected 
with the mutant IDH1 allele(E). 
 
mutations and drivers to best determine the cooperating nature among mutations 
identified in human patients.   
In addition to orthotopic intracranial injections, these NSCs also permit the study 
of more fundamental aspects of mutant IDH1 on a biologically relevant cell line.  For 
example, we are currently assessing the effects of mutant IDH1 on self-renewal of NSCs.  
Preliminary data shows that mutant IDH1 may be imparting an inhibition to the self-
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renewing capabilities of NSCs, an observation that corroborates the finding of a 
decreased number of proliferative cells of the SVZ in vivo.  Additionally, we are able to 
utilize these cells for differentiation studies and assess mutant IDH1’s effects on 
differentiation in vitro.  As differentiation is much easier to address in an in vitro system 
as opposed to an in vivo system, these NSCs will offer a tremendous advantage.  
Preliminary data shows that mutant IDH1 may be imparting a defect to the normal 
differentiation patterns of these cells, specifically into the neuronal lineage.  That is, 
when detecting β-(III)-tubulin positive cells, a marker for mature neurons, we observe 
that those cells expressing mutant IDH1 have a decreased propensity for differentiating 
into neurons when compared to their non-infected parental cell line.  This suggests that 
mutant IDH1 may be acting similarly in the CNS as it does in the hematopoietic system, 
that is, it confers a block to the differentiation. 
In conclusion, we have determined the genetic signatures of gliomas and utilized 
those signatures to generate genetically faithful mouse models that harbor those exact 
mutations found most commonly in the astrocytic subset of gliomas.  We have learned a 
great deal utilizing these models, including 1-Broad expression of mutant IDH1 induces 
hydrocephalus; 2-Mutant IDH1 induces hemorrhagic foci throughout the cortex of the 
brain when broadly expressed; a phenotype that may be due to aberrant HIF signaling 
as a result of elevated levels of 2-HG; 3-mutant IDH1 perturbs the NSC niche and this 
likely effects the many signaling pathways that are active in this area and imperative for 
 115 
the differentiation patterns of these cells of the CNS; 4-the NSC population in mutant 
brains tend to be more dispersed, suggesting mutant IDH1 may be imparting enhanced 
migratory abilities to these cells; 4- mutant IDH1, when co-mutated with TP53 is capable 
of inducing tumor development; 5-tumors that developed in these animals had higher 
levels of proliferative cells when compared to their wildtype counterparts; and 6-the 
survival of animals with mutant IDH1 and TP53 deletion was slightly better than in 
those animals with TP53 deleted alone.   
Ultimately, the system that encompasses the sequencing data from large-scale 
genomic studies to assess the contribution and significance of particular mutations, 
combined with the ability to promote tumorigenesis in an orthotopic manner as to 
preserve the microenvironment and signals from within, as well as depicting the 
heterogeneity observed in patient tumors, and to do so with high penetrance and short 
latency will be the most impactful of models.  In doing so, the model generated will 
provide the most stable foundation for preclinical data acquisition.  With the exception 
of tumor formation with high penetrance and short latency, which will be improved in 
our orthotopic intracranial injection system that we established that utilizes cells derived 
from our genetic model, we have reached the goals of this project.  With a foundation of 
the data presented here, together with the variety of models generated, we are poised to 
make great strides in understanding mutant IDH1’s contribution to tumorigenesis and 
ultimately, making an impact on this most fatal disease. 
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7.  Materials and Methods 
7.1.  Mouse husbandry 
All work requiring the use of animals was done in accordance with the Duke 
University Institutional Animal Care and Use Committee (DUIACUC) and in 
accordance with the National Institutes of Health Guide for the Care and Use of Laboratory 
Animals.  All work was performed under the approved animal protocol for Hai Yan: 
A072-13-03.  Animals were maintained in a barrier facility (Duke Cancer Center Isolation 
Facility) and were maintained according to NIH guidelines.  The animals were kept 
under pathogen-free conditions in sterilized plastic containers and were checked daily. 
7.2  Timed matings 
For experiments requiring treatment of animals with tamoxifen for an embryonic 
timepoint, animals were combined at a maximum of a 1:2 male:female ratio.  The 
morning following the establishment of the mating cage, animals were checked for the 
presence of a vaginal plug through the use of a probe.  The time the plug was identified 
was considered 0.5dpc.   
7.3  Treatment with tamoxifen 
Treatment of animals with tamoxifen was required to induce activation of Cre-
recombinase in those animals of the genotype Nestin-CreERT2.  Tamoxifen (Sigma, 
T5648) was made up in pharmaceutical grade corn oil at a concentration of 20mg/ml.  
Solution was warmed to 37° Celsius and vortexed thoroughly until completely 
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dissolved.  3mgs (150ul) of tamoxifen was administered to pregnant dams at 18.5dpc via 
oral gavage.  For P28 timepoints, adult animals were administered tamoxifen via oral 
gavage at a dosage of 1μg/kg.   
7.4  Euthanasia and tissue collection 
Every effort was made to ensure there was minimal pain and distress imparted 
on the animals.  Mice were checked daily for any signs of impairment or abnormalities 
and at the earliest indication of any distress, animals were sacrificed in accordance with 
the IACUC Policy for Animal Euthanasia.  Depending on the requirement of the tissues, 
adult animals were euthanized either through CO2 asphyxiation, followed by 
decapitation or through administration of a lethal dose of Urethane (10μl/g of 20% 
Urethane made up in sterile PBS).  Solution was administered through intraperitoneal 
injection.  Animals were monitored and toe pinches were performed to ensure they were 
unresponsive to pain.  Once unresponsive, animals underwent intracardiac perfusion 
with 15mls PBS followed by 15mls of 10% Neutral Buffered Formalin.  All procedures 
were done in accordance with our OESO approved SOPs.  Following perfusion, tissues 
were harvested and post-fixed in 10% Neutral Buffered Formalin for 24 hours at which 
time they were transferred to 70% Ethanol in preparation for paraffin embedding 
performed at the Duke University Pathology Research Histology and 
Immunohistochemistry Laboratory. 
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Animals sacrificed for the P3 timepoint were placed on ice until deeply 
anesthetized followed by decapitation and tissue harvesting.  Brains were placed in 10% 
Neutral Buffered Formalin for 24 hours at which point they were transferred to either 
70% Ethanol in preparation for paraffin embedding or in 20% Sucrose in PBS and placed 
at 4° Celsius until cryoprotected in preparation for OCT embedding. 
7.5  Tissue processing  
Tissues were either paraffin embedded or OCT embedded.  Paraffin blocks were 
cut 5-6μM and placed on charged microscope slides.  These slides were made for H&E 
staining and IHC procedures.  OCT blocks were cut at 14μM and placed onto charged 
microscope slides and stored at -80° Celsius until ready for IF procedure. 
7.6  H&E, IHC, and IF 
 Standard H&E procedures were performed requiring paraffin sections to 
undergo deparaffinization in 3 washes with Sub-X, followed by rehydration of the tissue 
in a graded Ethanol series, Hematoxylin staining, wash with Ammonia water, Eosin 
staining, dehydration in a graded Ethanol series, and a clearing in Sub-X followed by 
mounting with a Sub-X based mounting media. 
 Frozen sections were used for IF.  Briefly, tissues were permeablized and 
blocked, stained with primary antibodies (listed in Appendix C) made up in blocking 
buffer, and incubated overnight in a humidity chamber at 4° Celsius.  Slides were 
washed and incubated with secondary antibody made up in blocking buffer and 
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incubated at room temperature in the dark for 1-hour.  Slides were counterstained with 
DAPI and mounted.  
 For IHC, Zuowei Su of the Duke University Pathology Research Histology and 
Immunohistochemistry Laboratory followed a standard protocol requiring antigen 
retrieval in citrate buffer (pH 6.0, 80° Celsius) and utilizing the DAKO Autostainer 3400 
with antibodies listed in Appendix C.   
7.7  Imaging 
H&E and IHC samples were imaged using the Leica DMD 108.  IF images were 
imaged on the Nikon Eclipse T2000-E. 
7.8  Genotyping of animals: lysis, genomic DNA extraction, and 
PCR 
Toe-clips were collected from P9 animals or tail-snips were collected from P21 
animals.  Tissue was lysed overnight at 55° Celsius in lysis buffer (100mM Tris-HCl pH 
8; 5mM EDTA pH 8; 0.0% SDS; 200mM NaCl; Proteinase K, and water).  Solution 
containing tissue were vortexed and centrifuged at 14,000G for 10 minutes.  Supernatant 
was added to an equal volume of isopropanol and gently inverted until a precipitate 
formed.  The precipitate was transferred to 300μl 70% Ethanol, inverted, and centrifuged 
at 14,000G for 10 minutes.  Supernatant was removed and pellet was air dried for 10 
minutes.  Pellet was resuspended in 50 to 100μl of sterile H2O and further diluted 1:50 in 
sterile H2O.  1.5μl of diluted DNA were used for PCR reactions. 
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PCR master mixes contained the following:  1X Kapa Buffer A, 0.2mM dNTP, 6% 
DMSO, 1uM of forward primer, 1uM of reverse primer, and 0.3U Kapa2G Fast 
polymerase from Kapa Biosystems.  Primers and expected band sizes can be found in 
Appendix D.  Touchdown PCR protocol was perfomed:  1x (95°C 5 minutes); 3x (95°C 
20 seconds, 64°C 20 seconds, 72°C 20 seconds), 3x (95°C 20 seconds, 61°C 20 seconds, 
72°C 20 seconds), 3x (95°C 20 seconds, 57°C 20 seconds, 72°C 20 seconds), 30x (95°C 20 
seconds, 55°C 20 seconds, 72°C 20 seconds), 1x (72°C 5 minutes). 
7.9  NSC harvest and culture 
E14.5 embryos were utilized for NSC harvest.  Pregnant dams were sacrificed via 
CO2 asphyxiation followed by extraction of embryos.  Embryos were decapitated placed 
in dissection media (2% glucose on ice) and brains harvested under a dissection 
microscope.  Cortex of brain was triturated in Complete Embryonic NeuroCult 
Proliferation media and spun down at 150G for 5 minutes.  Cells were resuspended in 
Complete Embryonic NeuroCult Proliferation media and filtered through a 40μM filter.  
Cells were plated in Complete Embryonic NeuroCult Proliferation media at a density of 
1x105 cells per cm2.  For those cells harboring mutant alleles, induction with Cre-
recombinase was required.  1-day post harvest, cells were infected with Cre-expressing 
RGD fiber modified adenovirus (Vector Biolabs, 1769) at an MOI of 10-100.  24-hours 
post-infection, expression of mutant alleles or conditional tdTomato was observed 
through immunofluorescent imaging. 
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7.10  2-HG detection 
2-HG was detected in collaboration with the Pharmaceutical Research 
Pharmacokinetic/Pharmacodynamic Core Facility at Duke University.  The methodology 
for this process has been described previously(63). 
7.11  Sanger and exome sequencing 
Sanger sequencing and exome sequencing was performed as described in the 
following publications:  Jiao et al., 2012 and Killela et al., 2014 (35,36). 
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Appendix A 
Figures 3, 4, 9 and 27 as well as content in Chapter 2 and Appendix B were 
generated from currently published and copyrighted material.  All publications are 
available to reprint, modify, and copy as long as the original authors and source are 
cited under the Created Commons Attribution License: 
Jiao, Y., Killela, P. J., Reitman, Z. J., Rasheed, A. B., Heaphy, C. M., de Wilde, R. F., 
Rodriguez, F. J., Rosemberg, S., Oba-Shinjo, S. M., Nagahashi Marie, S. K., 
Bettegowda, C., Agrawal, N., Lipp, E., Pirozzi, C., Lopez, G., He, Y., Friedman, 
H., Friedman, A. H., Riggins, G. J., Holdhoff, M., Burger, P., McLendon, R., 
Bigner, D. D., Vogelstein, B., Meeker, A. K., Kinzler, K. W., Papadopoulos, N., 
Diaz, L. A., and Yan, H. (2012) Frequent ATRX, CIC, FUBP1 and IDH1 mutations 
refine the classification of malignant gliomas. Oncotarget 3, 709-722 
 
Killela, P. J., Pirozzi, C. J., Reitman, Z. J., Jones, S., Rasheed, B. A., Lipp, E., Friedman, H., 
Friedman, A. H., He, Y., McLendon, R. E., Bigner, D. D., and Yan, H. (2014) The 
genetic landscape of anaplastic astrocytoma. Oncotarget 5, 1452-1457 
 
Killela, P. J., Pirozzi, C. J., Healy, P., Reitman, Z. J., Lipp, E., Rasheed, A. B., Yang, R., 
Diplas, B., Wang, Z., Greer, P. K., Zhu, H., Wang, C., Carpenter, A., Friedman, 
H., Friedman, A. H., He, Y., McLendon, R. E., Herndon II, J. E., Yan, H., and 
Bigner, D. D. (2014) Mutations in IDH1 , IDH2 , and in the TERT promoter define 
clinically distinct subgroups of adult malignant gliomas. Oncotarget 5, 1515-1525 
 
A License Agreement for Figure 5 was obtained from Copyright Clearance Center and  
 
was reprinted by permission from Macmillan Publishers Ltd: Nature Publishing Group  
 
Prensner, J. R., and Chinnaiyan, A. M. (2011) Metabolism unhinged: IDH mutations in 
cancer. Nature medicine 17, 291-293. 
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Appendix B 
Recent studies have identified mutations in the promoter region of TERT in a 
variety of cancers including melanomas, liposarcomas, bladder cancer, urinary tract 
cancers, and gliomas.  TERT promoter mutations were found in a particular subset of 
gliomas and when combined with the mutation status of IDH1 or IDH2, had the ability 
to segregate the different glioma subtypes.  In our recent publication, we identify the 
presence of TERT promoter mutations specifically in oligodendrogliomas and primary 
GBMs, however mutations were not observed in the astrocytomas or secondary GBMs 
(Figure 27)(37).  Using the combined TERT promoter mutation status and IDH1/IDH2 
mutation status, we were able to distinguish the histologic subtypes; GBMs were 
characterized as TERT mutant/IDH wildtype, Grade II and Grade III astrocytomas 
characterized as TERT wildtype/IDH mutant, and the majority of Grade II and Grade III 
oligodendrogliomas were characterized as TERT mutant/IDH mutant.  Additionally, 
oligoastrocytomas, a subtype that presents a great deal of difficulty for 
neuropathological diagnosis were able to be depicted on a molecular level.  We also 
established that these genetic signatures are reliable when compared to the overall 
survival of patients derived from conventional histopathological diagnosis.  Mutations 
in the TERT promoter and in IDH1 or IDH2 effectively stratify patients into reproducible 
subgroups based on survival.  The strength of these genetic signatures and their 
association with overall survival are illustrated by a slightly higher R2 score than by 
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histology alone (0.3132 versus 0.2704).  This study supports genotyping of the TERT 
promoter and IDH1 and IDH2 as a rapid economical test requiring little tumoral DNA 
that could help inform clinicians both with regards to diagnosis and to predicted overall 
survival of patients.  Adapting this molecular means of diagnosis will promote 
consistency of diagnosis between institutions, thereby aiding in the stratification of 
patients and the examination of therapeutic response to treatment. 
 
 
Figure 27:  Distribution of TERT promoter and IDH1/2 mutations in a panel of 
473 adult gliomas. 
Mutational analysis of 473 adult gliomas for TERT promoter and IDH1/2 
mutations.  Data from 240 Grade IV GBM (A), 88 Grade II-III astrocytomas (B), 58 
Grade II-III oligoastrocytomas (C), and 87 Grade II-III oligodendrogliomas (D).  
Mutation status is indicated by color shading, with gray coloring indicating wildtype 
sequence, red indicating mutations in the TERT promoter, and green indicating 
mutations in IDH1/2. 
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Appendix C 
 
Table 3:  List of Antibodies 
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Appendix D 
Table 4:  Primer List 
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